Upload
khangminh22
View
1
Download
0
Embed Size (px)
Citation preview
1
17th June, 2020
David James Kerr
CBE, MA (Oxon), MBChB, BSc (Hons), MSc, PhD, MD, DSc, FRCP (Glasgow, Edinburgh and London), FRCGP (hon), FCanSci, FACP, FMedSci
CURRICULUM VITAE
Professor of Cancer Medicine, University of Oxford
Honorary Consultant Medical Oncologist, Oxford University Hospitals Trust
Honorary Prof of Oncology, Soochow University, China
Honorary Prof of Oncology, Sichuan University, China
Honorary Prof of Oncology, 2nd Military University of Shanghai, China
Honorary Prof of Oncology, Xiamen University, China
Honorary Professor of Oncology, Seoul National University, Korea
Honorary Professor of Latin American School of Oncology
Associate Editor, Journal of Global Oncology
2
CONTENTS
PERSONAL DETAILS ...................................................................................................... 3
EDUCATION ................................................................................................................. 4
POSTGRADUATE FELLOWSHIPS AND PRIZES .................................................................. 5
MEDICAL ONCOLOGY CAREER ....................................................................................... 6
CURRENT APPOINTMENTS ............................................................................................ 6
MEMBERSHIP OF SOCIETIES ......................................................................................... 8
CLINICAL AND SCIENTIFIC LEADERSHIP ....................................................................... 11
CLINICAL DUTIES ........................................................................................................ 11
TRANSLATIONAL CANCER RESEARCH: GENE THERAPY OF CANCER ................................. 12
INTERACTION WITH INDUSTRY .................................................................................... 14
INTERNATIONAL COLLABORATIONS: ............................................................................ 14
ORGANISATIONAL LEADERSHIP .................................................................................... 12
RESEARCH GRANTS RECEIVED ..................................................................................... 14
PUBLICATIONS ............................................................................................................ 19
PUBLISHED ABSTRACTS ............................................................................................... 20
THESES ....................................................................................................................... 20
PEER REVIEWED PUBLICATIONS................................................................................... 20
PUBLISHED BOOK CHAPTERS ....................................................................................... 49
EDITED BOOKS............................................................................................................ 51
JOURNAL EDITORIAL BOARDS ...................................................................................... 51
3
PERSONAL DETAILS
Address Mollington House, Mollington, Oxon OX17 1 AX Telephone No +44 1295 750004 +44 7976708535 (mobile) Email Address [email protected] GMC Reg No 2548216 Nationality British Marital Status Married (5 children) Languages English, working French and Arabic
4
EDUCATION
University of Glasgow
Degrees
Science degrees
University of Oxford
HONOURS and FELLOWSHIPS
MBChB 1980
MD
Aspects of Cytotoxic Drug Penetration
1987
BSc First class honours in Biochemistry and Gold Medallist 1977
MSc in Clinical Pharmacology 1990
PhD Regulation of proliferation of breast cancer cells by growth factors 1990
DSc The molecular and clinical pharmacology of anticancer therapy 1996
MA 2002
Elected Fellow of Royal College of Physicians and Surgeons, Glasgow (FRCP, Glas)
Elected Fellow of Royal College of Physicians, London (FRCP, Lon)
Elected Fellow of Academy of Medical Sciences (FMed Sci)
Awarded Commander of Order of British Empire, by HM the Queen (CBE)
1995
1996
2000
2002
Elected Honorary Fellow of Royal College of General Practitioners (FRCGP) 2007
Elected Founding Fellow of European Academy of Cancer Sciences (F Can Sci )
2009
Elected Fellow of Royal College of Physicians, Edinburgh (FRCP, Edin) 2010
Adjunct Professor of Medicine, Weill-Cornell College of Medicine (NY) 2011-17
Honorary Prof of Oncology, 2nd Military University of Shanghai, China 2016-current
Honorary Prof of Oncology, Xiamen University, China 2016-
current Honorary Professor of Oncology, Seoul National University, Korea 2016 –
current Honorary Professor of Oncology, Sichuan University, China
Honorary Professor of Oncology, Soochow University, China
Elected Fellow of Association of Cancer Physicians (FACP) Honorary Professor of Latin American School of Oncology
Elected Fellow of the College of European School of Oncology
2018-
current
2019 2019
2020
5
POSTGRADUATE FELLOWSHIPS AND PRIZES
Alexander Fletcher Memorial Prize, Royal College of Physicians and Surgeons for distinguished
research into thyroid cancer
1987
European School of Oncology International Award for outstanding contribution to
chemotherapy research
1987
Graham Wilson Travelling Fellow, University of Glasgow 1988
British Association for Cancer Research Fellowship 1988
International Union against Cancer - Cancer Research Fellowship International Cancer Research
Exchange Technology Transfer Grant
1989
May and Baker Prize for essay on Aspects of Therapy Royal College of Physicians & Surgeons, Glasgow
1991
Pauline TSU Memorial Lecture, Royal College of Physicians & Surgeons, Edinburgh 1992
International Society of Geriatrics - Zeneca Lecture "Treatment of cancer in the elderly" 1995
Royal Society of Art Annual Lecture 1995
10th Erasmus Darwin Lecture 1996
2nd International Prize for Excellence in the field of Colorectal Cancer Research and
Treatment
1999
1st Nye Bevan Award for Innovation – Awarded by NHS for Gene Therapy Research
AstraZeneca: Oncology and Infections Vision and Values Award
2000
2005
Distinguished Medeval Lecture, University of Manchester 2006
European Society of Medical Oncology Award for distinguished contribution to Cancer therapy and research in Europe
2006
Fulton Lecture, University of Glasgow 2007
Bruce Cain Memorial Lecture, Cancer Societies of Australia and New Zealand 2008
Honorary Fellow of Hungarian Oncology Society 2016
Harvard Global Health Catalyst: Distinguished Leader Award, in recognition of his many years of leadership in global health work
2017
6
MEDICAL ONCOLOGY CAREER
University of Glasgow
Prof S B Kaye CRC Dept of Medical Oncology,
CRC Research Fellow (Honorary Registrar)
April 1984 - September 1986
Beatson Institute for Cancer Research, Honorary Senior Registrar
October 1986 - September 1988
MRC Recombinant DNA Training Fellowship
CRC Senior Research Fellow, Hon Senior Registrar
October 1988 - June 1989
CRC Senior Fellow, Senior Lecturer in Medical
Oncology and Honorary Consultant Physician and Pharmacology Group Leader
CRC Dept of Medical Oncology,
July 1989 - February 1992
Honorary Professor of Pharmacology, University
of Strathclyde
July 1990 – present
University of Birmingham
Professor of Clinical Oncology and Clinical
Director, CRC Institute for Cancer Studies,
March 1992 – 2001
Honorary Consultant Physician, Birmingham
Oncology Centre, Queen Elizabeth and City Hospitals
March 1992 – 2001
University of Oxford
Director, National Translational Cancer
Research Network
October 2001 – April 2006
Rhodes Professor of Cancer Therapeutics and Clinical Pharmacology;
Head of Department Clinical Pharmacology;
Fellow, Corpus Christi College , Oxford;
Honorary Consultant in Medical Oncology - Radcliffe Hospital Trusts
October 2001 – March 2009
7
Sidra Medical and Research Centre,
Doha, Qatar (leave of absence from
Oxford)
Chief Research Advisor
Member, Supreme Health Council, State of
Qatar
Professor of Cancer Medicine, University of
Oxford
Adjunct Professor of Medicine, Weill
Cornell Medical College
Honorary Consultant in Medical Oncology
– Al Amal Hospital, Doha and Oxford
University Hospital Trust
Professor of Cancer Medicine,
Nuffield Division of Clinical and Laboratory Sciences, 2010 – present
Honorary Consultant in Medical Oncology, Oxford University Hospitals Trust
Seconded as Health Adviser to Sec State for
Health ,UK October, 2010 – August, 2012
Adjunct Professor of Medicine, Weill Cornell
Medical College, 2009 – 2017
Honorary Professor, 2nd Military University of Shanghai 2015-Present
Honorary Professor, University of Xiamen Honorary President of Xiamen University
Hospital Cancer Centre 2015-present
Honorary Professor, University of Sichuan and
West China Hospital 2018- present
Honorary Professor, University of Soochow 2019 - present
Honorary Professor, Seoul National University, Korea 2016-present
March 2009 – October 2010
October, 2010 - current
8
President, European Society of Medical
Oncology, 2009 – 11
Chief Medical Officer, Celleron Therapeutics 2012– present
Ed in Chief, J of Global Oncology, 2015 - 17
MEMBERSHIP OF SOCIETIES
British Oncology Association
British Association for Cancer Research
European Society of Medical Oncology
Association of Cancer Physicians
European Association for Cancer Research
American Association for Cancer Research
American Society for Clinical Oncology
9
MEMBERSHIP OF EXECUTIVE COMMITTEES
Local
University of Oxford
▪ Committee of Heads of Departments of Science, 2001-2009
▪ Committee of Heads of Departments of Medical School, 2001-2009
▪ Chair, Biomedical Sciences Prize Committee, 2005-2009
▪ Central Committee for Estates (representing Division of Medicine), 2006-2009
National
Medical Research Council, Molecular and Cell Medicine Board, Committee A, Member (1993-1997)
Medical Research Council, Colorectal Cancer Working Party, Member - responsible for co-ordinating
two international trials in advanced colorectal cancer. (1992-2003)
Medical Research Council, Clinical Fellowships Panel. (1993-1996)
Medical Research Council, Realising Our Potential Awards Committee.(1995-1996)
Medical Research Council, LINK with Industry Panel. (1995)
Advisory Group to Commission for Health Improvement (1998)
Cancer Research Campaign, Clinical Trials Committee, Member (1998-2001)
Chairman, National Cancer services Collaborative (budget £30 million). (1999 – 2003)
Chairman and Clinical Lead, Department of Health Audit on Cancer Waiting Times. (1999)
Founding Commissioner, Commission for Health Improvement.(1999-2001)
Cancer Research Campaign, Site Visit Committee member and responsibility for grant reports.
Adviser, Commonwealth Scholarships and Fellowships (1999 – present)
National Cancer Task Force, Member. (2000 – 9)
Director of National Translational Cancer Research Network (2001- 2006)
Chairman National Cancer Research Institute’s adjuvant colorectal cancer trials group (2003 – 8)
Member, National Colorectal Cancer Advisory Group (2003 – 9)
Member, Department of Health Research for Patient Benefits Working Party (2003- 2005)
Chairman, National Framework for NHS in Scotland: Advisory Group (2004 – 2005)
Member, Health Bill Working Group (2011-12)
Member, National Stakeholder’s Forum, (2012- current)
10
International
Pan European Trial of Adjuvant Chemotherapy for Colorectal Cancer – Trial Steering Committee,
UK Chairman (1995-1998)
European Society for Medical Oncology, Chairman of Scientific Committee - responsible for
arranging and ensuring a high scientific content of ESMO Athens meetings (1998)
American Society for Clinical Oncology - international liaison committee of senior European and
American oncologists linking ESMO and ASCO meetings (1998)
International Working Party on Colorectal Cancer: this group consists of senior academics from
USA and each European Country with an interest in the treatment of colorectal cancer.(1999)
EORTC, Gastro-intestinal Study Group, Member - responsible for trans-European studies in a range
of gastro-intestinal cancer. (1998 – present)
Editor-in-Chief, Annals of Oncology; scientific journal of European Society of Medical Oncology and
Europe's leading clinical cancer journal. (1999 – present)
US National Institute of Health Colorectal Cancer Research Strategy Group – overseas member,
2000
Co-Chairman, Scientific Steering Committee for centenary celebration of Entente Cordiale –
“Today’s Science, Tomorrow’s Patient” 2003 – 2005)
US National Cancer Institute – Translational Research Working Group (sole overseas member)
2005-2007
European Society of Medical Oncology, Presidential Cycle, 2008-2014
Chairman of INDOX – www.indox.org.uk – 2005 to date
Chairman of AfrOx – www.afrox.org – 2007 – to date
Member of International Scientific Advisory Board for Center for Translational
Molecular Medicine, The Netherlands – 2008 (present distribution of 500 million Euros)
Member of International Assessment Committee for Research Hospital Fund of
Canadian Foundation for Innovation: distribution of $500 million, 2008
Member of Advisory Board of the Centre for Cancer Biomedicine, The Norwegian
Radium Hospital, Norway, 2008 - date.
Member of Scientific Advisory Board of Institut Gustav Roussy, Paris (2009- to date)
Supreme Council of Health, Qatar (2009 – 10)
11
CLINICAL AND SCIENTIFIC LEADERSHIP
Working in partnership with Professor Alan Rickinson FRS. I established the CRC Institute for Cancer
Studies in University of Birmingham, built the scientific establishment from around 50-60 staff to 150-
200 and secured funding to construct a new laboratory to house the expanded workforce. I supported construction of a new cancer hospital in Birmingham, forged a series of innovative clinical practices,
founded clinical gene therapy in Birmingham and spun out a small biotech company, COBRA Therapeutics.
Appointment to the Rhodes Chair of Cancer Therapeutics and Clinical Pharmacology (October, 2001), University of Oxford has allowed me to work with Sir John Bell to build a new Institute for Cancer
Medicine in Oxford, (£60 million) contiguous with the new cancer hospital (£125 million) on the Churchill Biomedical Campus.
This work was recognised by award of CBE (2002) by HM the Queen.
CLINICAL DUTIES and COLORECTAL CANCER RESEARCH
In Oxford I have joined the multidisciplinary gastro-intestinal cancer team, established a contract with
the Danish Government to see and treat their refractory liver cancer patients, developed a gastrointestinal cancer study group within my Clinical Trials Unit and have accrued large patient
numbers to local, national and international studies. Richard Gray and I ran QUASAR, a trial of adjuvant chemotherapy in colorectal cancer which successfully recruited 8500 patients in 8 years making it one
of the largest and therefore potentially most influential cancer trials in the world. This has continued in
Oxford with VICTOR, a placebo-controlled study of a selective COX-2 inhibitor, rofecoxib in an adjuvant setting for CRC which has recruited 2,500 patients. QUASAR 2 (3,750 patients) will compare standard
chemotherapy versus Capecitabine and Bevacizumab, a regime which was developed in our own unit. This work has established the UK and my Unit as international leaders in the field of treatment and
research into colorectal cancer. More recently, we have extended this work through collaboration with Prof Ian Tomlinson into the field of Genome Wide Association studies, with notable success.
Contribution to the field of colorectal cancer research and treatment was recognised in 1999 by the award of the 2nd International GI Cancer prize by the Institute for Drug
Development and European Association for Research into Gastrointestinal Cancer and the ESMO award, 2006.
Establishing a joint GI Cancer Research Centre with Sichuan University and Huaxi Hospital, 2020
12
TRANSLATIONAL CANCER RESEARCH
I have been involved in cancer drug development for 30 years and established a phase I Trials Unit in the University of Birmingham to develop an MRC-funded virus-based gene therapy programme. I joined
the Oxford Cancer Centre experimental trials group working with consultant colleagues, Prof Mark
Middleton and Professor Adrian Harris with approximately 200-300 patients referred per annum for consideration of novel therapy with signal transduction inhibitors from the Pharma industry and our
own account gene therapy programme (preclinical lead is Professor Len Seymour). I have conducted approximately 30 phase 1 trials.
Contribution to the field of gene therapy was recognised by award of the NHS’ first Nye Bevan award for Research Excellence.
ORGANISATIONAL LEADERSHIP
Academic (Universities of Birmingham and Oxford): As documented previously, I played a significant role in partnership with Alan Rickinson FRS, in establishing the CRC Institute for Cancer
Studies in Birmingham and leading its development to one of the largest and best funded academic
departments in the University of Birmingham. I was asked to do the same in Oxford, working closely with Sir John Bell, with a vision of constructing a comprehensive cancer centre. We secured funding
from the Department of Health for a new cancer hospital (£125 million) and have raised £60 million for the new laboratory. Importantly, in a time of increasing academic compartmentalisation, I established
a series of collaborations across different divisions (Biomedical Engineering, Chemistry, Said Business
School, Mathematics and Computer Science).
National Translational Cancer Research Network (NTRAC):
I was commissioned by Secretary of State for Health to devise a costed blue print for provision of
infrastructure to support clinical cancer research in the UK (NCRN and NTRAC). This was accepted and funded (£100 million) as part of the National Cancer Plan and I was subsequently appointed Director
of NTRAC. This was a fascinating challenge, working with the best cancer research centres in the UK
to forge them into a collaborative network, greater than the sum of its component points. International recognition of NTRAC’s ground breaking work has come in the form of invitations to; establish jointly
funded translational science research fellowships between NTRAC and the NCI Washington and the French government’s Canceropoles; develop a European wide plan (ETRAC) to construct a Network of
its top comprehensive cancer centres, along very similar lines to NTRAC; shape the Danish
government’s plan to fund early clinical trial centres; provide intellectual underpinning for the US National Cancer Tissue Bank. NTRAC served as a ground breaking blue print for the other Department
of Health innovations in forming research networks for cardiovascular disease, diabetes, mental health etc.
National Health Service, UK: Under the auspices of Brian Edwards, Chief Executive of West Midlands
Regional Health Authority, I assembled a cancer services task force, developed a delivery strategy, and led the Regional team in its implementation over a 4 year period (1993-1997). This involved writing
a Cancer Plan defining the relevant standards and the evidence base supporting these. The “hub and spoke” Network model which we elected to use has been developed further and incorporated into the
National Cancer Plan, and we boiled the predicant philosophy down to four key elements:
Site specialisation by cancer surgeons and oncologists
Multidisciplinary working
Development of regional treatment guidelines (often precursor of national guidelines)
Use of IT as a social glue to bind the Network together.
13
This led to national investment in Cancer Services and fed forward into improving our National
cancer survival figures and governmental investment of £670 million.
Department of Health: There are four National Programmes which I have led on behalf of the DH which have involved taking a strategic overview, finding effective solutions to complex problems and
initiating cultural change in the NHS:
National Audit of Cancer Waiting Times (1999): I delivered the first set of comprehensive data on cancer waiting times across the entire health service in England. This information was presented to
ministers and was so profoundly disturbing, given the length of delays, that it was one of the dominant strands which resulted in creation of a National Cancer Plan - British Medical Journal 320, 838-839.
Founding Commissioner For Health Improvement (1999-2001): I was invited to become a founding Commissioner stemming from an earlier piece of work in which I supported the main
committee established to define CHI’s roles and responsibilities. I chaired the first review of the
National Service Framework on Cancer Services, performed jointly with the Audit Commission (CHI-Audit Commission report on Cancer Services, 2000) its publication helped to highlight those areas of
the cancer plan which were most vulnerable so that appropriate action might be taken and celebrate the obvious successes. Perhaps most importantly, we wrote this document so that it would be
accessible to the lay reader and published a series of questions (in collaboration with the Guardian and
Mirror) that patients could pose to their medical teams to ensure that they were getting optimal care.
Cancer Services Collaborative (1999-2003): Seeing the need to reform the mode of delivery of
cancer services, Helen Bevan (Director of Redesign, NHS Institute) and I secured funding to work with Don Berwick (Institute for Health Improvement, Boston) to create the Cancer Services Collaborative,
the largest health care redesign programme ever undertaken. Results are detailed on web site (http://www.modern.nhs.uk), but in summary, significant gains were made in waiting times across the
cancer patient’s journey, a much larger proportion of cancer patients were discussed by multidisciplinary
teams and the quality of available patient information was greatly enhanced. This involved engagement with an initially sceptical clinical community and delivery of a complex National programme. The
Cancer Services Collaborative involved expenditure of £30 million over 3 years, a staff of approximately 300 facilitators, managers and clinicians, which at its peak was reporting 1000 change episodes per
month. We gained unique insights into large scale change management, the important elements of
evincing clinical engagement, the problems associated with spread and sustainability of new practice and how we could use innovative communication practice to build a modernisation movement.
National Framework for Service Change in NHS Scotland (2004-2005): I was invited by Scotland’s First Minister to chair the work of a National Framework Advisory Group to consider the
future shape of the NHS in Scotland. We produced three volumes of work, “Building a Health Service
Fit for the Future” (Vol I and II) and a web-based data link showing the Reports from the individual action teams (www.show.scot.nhs.uk/national framework). The eponymous Kerr Report received
strong support from citizens, health care professionals, unions (BMA and RCN), media and cross-party parliamentary endorsement. It has been adopted as the blueprint for Scotland’s NHS over the next 20
years.
Sidra Medical and Research Centre (2009-2010): I was employed by Her Highness Sheikha
Mozah, Consort of the Emir of Qatar to build the Research Division of the Sidra Medical and Research
Centre, supported by the largest hospital endowment in the world ($9 billion). I practiced medicine at the local cancer hospital, Al Amal, and was appointed to the Supreme Council of Health, effectively
Qatar’s Health Cabinet and was one of three authors of Qatar’s 20/20 Vision National Health Plan. This position has allowed me to develop links with the wider world of Islam through the Organisation of the
Islamic Conference (OIC).
Health Adviser to PM David Cameron and Conservative Party (2010-12 )
I have supported the intellectual underpinning of the NHS’ White Paper and provided a clinical Advisory role to former Prime Minister David Cameron and Health Secretary Andrew Lansley.
14
INTERACTION WITH INDUSTRY
I have established board level links with a number of global pharmaceutical and healthcare companies
which has led to significant grant funding eg Glaxo Smith Kline (£3 million), Merck (£14 million), Roche (£6.5 million) GE Healthcare (£2 million) and AstraZeneca (£1 million). I was part of the Drug
Development Team which won Astra Zeneca’s Oncology and Infections Visions and Values prize in 2005.
When working in the University of Birmingham, I established one of their first biotechnology spin outs, a gene therapy company, COBRA Therapeutics. In Oxford, I have worked with Prof Nick La Thangue
to construct a cancer drug development company, Celleron and Oxford Cancer Biomarkers a platform technology-based biotech company which identifies chemotherapy sensitivity biomarkers.
INTERNATIONAL COLLABORATIONS:
USA I sat on NIH’s Translational Research working group as the overseas member and
have established a series of collaborations with the USA’s major cancer research centres (Mayo Clinic, MD Anderson, Memorial Sloan Kettering and Dana Farber,
Harvard).
INDIA having attracted grant funding from the pharmaceutical companies GSK and Sanofi-Aventis, we have constructed a network of India’s top 10 cancer centres, in
partnership with Oxford. This collaboration provided training opportunities for Indian investigators in Oxford and built an internationally competitive clinical
research network (www.indox.org.uk ).
EUROPE I had the opportunity to co-chair the Entente Cordiale Celebrations on behalf of HM the Queen and President Chirac, 2003-2005. As President of ESMO (2010-
2012) I improved the standing of Medical Oncology in Europe and sat on the Dutch government’s central committee for translational research (CTMM) with a budget
of 1 billion Euros.
AFRICA I have established a consortium comprising the International Atomic Energy Agency, International Agency for Cancer Research, and the Union Internationals
Contre Le Cancer to develop cancer control programmes in Sub Saharan Africa and
created AfrOx (www.afrox.org) the vehicle to implement change. We have worked with governments in Ghana, Nigeria and Kenya to improve national cancer plans.
FAR EAST I established the Cancer Care Commission which has formed a Joint Venture with China Resources Medical to improve cancer planning and care in China.
I am an Honorary professor at several major Chinese Universities and support
teaching and research activities and established a joint GI Cancer Research Centre with Sichuan University and Huaxi Hospital, 2020.
15
RESEARCH GRANTS RECEIVED
1989
Health Board Research Support Group - £10,000.
One year's salary for Research Assistant.
EEC (European against cancer initiative) - £230,000 over two years as part of an international collaborative group chaired by Prof S S Davis, Dept. Pharmacy,
University of Nottingham
Cancer Research Campaign Project Grant - £160,000.
3 years' salary - clinical research fellow & post doctoral scientist for research into use of Mitomycin C microcapsules by intrahepatic arterial administration in hepatic metastatic
carcinoma.
Grant Holders - D Kerr, C McArdle, A Whately.
1990
Scottish Hospital Endowment Research Trust- £44,000
2 year's salary for research assistant - molecular biology of breast cancer
Cancer Research Campaign - £80,000 over 3 years Joint project with Dr I Pragnell, Beatson Institute for Cancer Research, funding a clinical
research fellow to investigate preclinical toxicology of marrow stem cell inhibitor
1991
Scottish Hospital Endowment Research Trust - £75,000
3 year salary for senior post-doctoral scientist for project on population pharmacokinetics of cytotoxic drugs in breast cancer therapy
Cancer Research Campaign - £200,000 per annum Supervision of programme grant expenditure of CRC Pharmacology Group - 5 year programme
Grant.
1992
Scottish Hospital Endowments Research Trust - £50,000
2 year's salary for senior post-doctoral scientist for project on formulation of cytotoxic drugs for cerebral implantation in the treatment of brain tumours.
Grant Holders - D J Kerr, T A Whately, R Rampling, J Plumb
Queen Elizabeth Endowment Trust - £42,000
Development of Inhibitors of P-Glycoprotein. Grant Holders - D J Kerr, D R Ferry
Queen Elizabeth Endowment Trust - £27,000
Interaction of Platinum with the HIV Promoter Sequence. Grant Holders - D J Kerr, C J Poole, L Young
Cancer Research Campaign - £500,000
16
Laboratory Refurbishment grant on joining University of Birmingham
Grant Holder – D J Kerr
Cancer Research Campaign - £620,000 Molecular Pharmacology Group
Grant Holder – D J Kerr
Cancer Research Campaign - £1 million
Programme Grant Supporting Clinical Trials Unit Grant Holder – D J Kerr
1994
Regional Health Authority- £5 million To house the expanding Institute for Cancer Studies
Grant holder - D J Kerr
September 1995-September 1999
Medical Research Council £1,501,304
Gene Therapy of Common Cancers: Immunological & Pharmacological Approaches to Gynaecological Cancer.
Grant holders - LS Young, PF Searle, D. Luesley, AB Rickinson, PH. Gallimore
Cancer Research Campaign £1.25 million
Departments Expenses-Core Funding 1995-1999 Grant holders - AB Rickinson and DJ Kerr
September 1994-September 1997
Glaxo Research and Development Limited (plc) - £75,000 A Co-administration of rising oral GG918 Dose Levels with Doxorubicin Phase 1 Study
Grant holders - DJ Kerr
January 1995-January 1998
M.L. Laboratories plc - £75,794
Adjuvant Intraperitoneal Chemotherapy with 5-fluorouracil in Duke’s Stage B and C Colic Adenocarcinoma (VICTOR)
Grant holder - DJ Kerr
November 1995-November 1997
Special Trustees of the Former UBH Trust £49,233
Investigation of Phospholipase Signal Transduction Pathways in Human Breast Cancer Grant holders - DJ Kerr and MJO Wakelam
March 1997-March 1998
Takeda Chemical Industries Ltd. (Japan) £42,000 A Phase II Open Label Study to Determine the Safety Tolerability and Efficacy of CV6504(HCI)
in Patients with pancreatic cancer Grant holders - DJ Kerr
September 1996-September 1999
Glaxo-Wellcome R and D £120,000
17
Immunological and Pharmacological Aspects of Gene Therapy
Grant holders - DJ Kerr
1996-2001
Cancer Research Campaign £616,335
Core Clinical Fellowships Grant holders - DJ Kerr
1997-2001
Cancer Research Campaign £1,102,030
Clinical Trials Unit – Core Support Grant holders - DJ Kerr
1995-1998
Cancer Research Campaign £68,526 West Midlands Trials of Adjuvant Treatment in Early Breast Cancer
Grant holder - DJ Kerr
1998-2003
Cancer Research Campaign £534,695
Pre-Clinical and Clinical Pharmacology and Macromolecular Drug Targeting Grant holder - DJ Kerr
1998-2002
Cancer Research Campaign £135,690 ATTOM UKCCCR Randomised Trial to Establish Optimum Length of Adjuvant Tamoxifen
Grant holder - DJ Kerr
1994-1997
Ministry of Agriculture, Fisheries and Food £200,742
Evaluation of Non-Nutrient Dietary Constituents in Prevention of Breast Cancer Grant holders - DJ Kerr, A Gescher, K. Chipman
1997
The Higher Education Funding Council Capital £249,640 Research and Development for a Boron Cancer Therapy Clinical Facility
Grant holders - DJ Kerr, N James, D. Beynon
1996-2001
NHS Research and Development Office £2.2 million
Foundation of a Regional Clinical Trials Unit Grant holders - DJ Kerr, R Hobbs, L Ward, J Dunn, J Kenkre
1994-1999
Medical Research Council £1.36 million QUASAR Adjuvant Trial of Colorectal Cancer Chemotherapy
Grant holders - DJ Kerr and R Gray
18
1998
Wellcome Trust £2.8 million Construction of a clinical research facility
Grant holders – M Sheppard, P Stewart, DJ Kerr, M Wakelam, LS Young, AB Rickinson, C Savage
1998-2003
Medical Research Council £403,608
Co-operative Group – Translational Research: Gene and Immunotherapy of Cancer. Grant holders: DJ Kerr, DH Adams, PAH Moss, V Mautner, PF Searle, L Seymour and LS Young
Medical Research Council £68,240 Joint Research Equipment Initiative Award
Grant Holders: P Moss, A Rickinson, D Kerr, J Gordon, L Young C Bunce
1997-2002
Zeneca Pharmaceuticals £1,130,000
Clinical Trials Grant for Adjuvant Colorectal Cancer Trial: PETACC
Medical Research Council £600,000
FOCUS : trial of chemotherapy in advanced colorectal cancer Grant Holders: M Seymour, R James, D J Kerr, T Maugham and R Stephens
Recently awarded grants
MERCK – Cancer Research Campaign £12.6 million – 2002 – 2009
Trial of adjuvant therapy with cyclooxygenase inhibitors in colorectal cancer Grant Holder: D J Kerr
Roche/Aventis – Cancer Research Campaign £4 million – 2004 - 2009 Adjuvant trial of chemotherapy for colorectal cancer
Grant Holder: D J Kerr
Genomic Healthcare £83,330 - 2006-2008 Proteomic investigation of colorectal cancer
Grant holder: D J Kerr
NHS R & D £20 million - 2001 – 2006
To establish the National Translational Cancer Research Network (NTRAC) and the National Cancer Tissue Resource (NCTR).
Grant Holder: D J Kerr
E-Science Pilot Project in Integrative Biology - £ 1,244 310
Lead investigator: D Gavaghan Co-investigator: D J Kerr
CRUK Gene Therapy Programme Grant - £1.2 million - 2004 - 2009
Lead investigator: L Seymour
Co-investigator: D J Kerr
19
Genomic and proteomic approaches to identify novel Markers of Colorectal Cancer, MRC Co-operative
Grant: £215,788 – 2004 -2007
Lead investigators: D J Kerr and I Tomlinson
GE Healthcare: Molecular Basis of Colorectal Cancer - £2.4 million – 2005-2007
Lead Investigator: D J Kerr
Cancer Research UK, Research Grant, ECMC Award - CRUK funding for the experimental cancer medicine centre - £3,070,410 - 2007 – 2012
Lead investigator: A Harris Co-investigator: D J Kerr
EUROCAN: £80,421- 2005 – 2007 Lead investigator: P Boyle Co-investigator: D J Kerr
SCOT Study ad adjuvant colorectal cancer chemotherapy: MRC £1,798,433 – 2006- 2014 Lead investigator: J Cassidy
Co-investigator: D J Kerr
Roche Ltd: £1.5 million – 2012 – 2015
Lead Investigator: DJ Kerr
Oxford Cancer Biomarkers: £8 million – 2011- current; co-founders, DJ Kerr & N La Thangue
Discovery of Colorectal Cancer Biomarkers: £10 million. 2016 2020
Norwegian Research Council. Lead Investigator: Havard Danielsen ; co-investigator: DJ Kerr
Celleron Therapeutics: £ 12.5 million – 2016-current; co-founders, DJ Kerr & Nick La thangue
Oxford-Sichuan GI Cancer Research Centre: £5 million – 2020 – current, DJ Kerr and Li Yang
20
PUBLICATIONS
PUBLISHED ABSTRACTS
Over 300 Abstracts presented at national and international conferences.
H-Index 95 Citations 45,000
THESES
BSc Degradation of the neuropeptide, met enkephalin by human plasma
MSc The clinical pharmacology of LM985 - an experimental cytotoxic drug
MD Aspects of cytotoxic drug penetration
PhD Regulation of proliferation of breast cancer cells by growth factors.
DSc The Molecular pharmacology of anticancer therapy
PEER REVIEWED PUBLICATIONS
In 4 sections: Colorectal Cancer; Drug Development; Gene Therapy; General Medicine
Section 1: Colorectal Cancer
Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019) Ren L, Zhu D, Benson AB, Nordlinger B, Koehne C-H, Delaney CP, Kerr D, Lenz H-J, Fan J, Wang J et al European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20 Feb 2020 Deep learning for prediction of colorectal cancer outcome: a discovery and validation study Skrede O-J, De Raedt S, Kleppe A, Hveem TS, Liestøl K, Maddison J, Askautrud HA, Pradhan M, Nesheim JA, Albregtsen F, Farstad IN, Domingo E, Church DN, Nesbakken A, Shepherd NA, Tomlinson I, Kerr R, Novelli M, Kerr DJ, Danielsen HE Lancet 395(10221):350-360 Feb 2020 Association analyses identify 31 new risk loci for colorectal cancer susceptibility Law PJ, Timofeeva M, Fernandez-Rozadilla C, Broderick P, Studd J, Fernandez-Tajes J, Farrington S, Svinti V, Palles C, Orlando G, Sud A, Holroyd A, Penegar S, Theodoratou E, Vaughan-Shaw P, Campbell H, Zgaga L, Hayward C, Campbell A, Harris S, Deary IJ, Starr J, Gatcombe L, Pinna M, Briggs S Kerr DJ Tomlinson I Houlson R and Dunlop M Nature Communications 10(1):Article number 2154 14 May 2019
21
Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial Barrow P, Richman SD, Wallace AJ, Handley K, Hutchins GGA, Kerr D, Magill L, Evans DG, Gray R, Quirke P, Hill J Histopathology 75(2):236-246 Aug 2019 Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer. Ersvaer E, Hveem TS, Vlatkovic L, Brennhovd B, Kleppe A, Tobin KAR, Pradhan M, Cyll K, Waehre H, Kerr DJ, Danielsen HE International journal of cancer 17 Dec 2019 Cancer immune evasion in gastrointestinal cancer: Can this be overcome by combination of histone deacetylase and immune checkpoint inhibitors? Shi Y, Duru O, Zou Z, Kerr D Frontiers in Clinical Drug Research 5:50-84 01 Jan 2019 Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. Jiang W, Cai M-Y, Li S-Y, Bei J-X, Wang F, Hampel H, Ling Y-H, Frayling IM, Sinicrope FA, Rodriguez-Bigas MA, Dignam JJ, Kerr DJ, Rosell R, Mao M, Li J-B, Guo Y-M, Wu X-Y, Kong L-H, Tang J-H, Wu X-D, Li C-F, Chen J-R, Ou Q-J, Ye M-Z, Guo F-M, Han P, Wang Q-W, Wan D-S, Li L, Xu R-H, Xu R-H, Pan Z-Z, Ding P-R, Written on behalf of AME Colorectal Cancer Cooperative Group International journal of cancer 144(9):2161-2168 May 2019 An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance Li N, Babaei-Jadidi R, Lorenzi F, Spencer-Dene B, Clarke P, Domingo E, Tulchinsky E, Vries RGJ, Kerr D, Pan Y, He Y, Bates DO, Tomlinson I , Clevers H, Nateri AS Oncogenesis 8(3):13 19 Feb 2019 Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage Glaire M, Domingo E, Sveen A, Bruun J, Nesbakken A, Nicholson G, Novelli M, Lawson K, Oukrif D,Kidal W et al British Journal of Cancer 121:474-482 07 Aug 2019 A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer Eyre TA, Collins G, Gupta A, Coupe N, Sheikh S, Whittaker J, Wang L, Campo L, Soilleux E, Tysoe F, Cousins R, La Thangue N, Folkes L, Stratford M, Kerr D, Middleton M Cancer 125(1):99-108 17 Oct 2018 Mutation burden and other molecular markers of prognosis in the QUASAR2 clinical trial of colorectal cancer treated with curative intent Mouradov D, Pentony MM, Makino S, Palmieri M, Ward RL, Hawkins NJ, Gibbs P, Askautrud H, Oukrif D, Wang H, Wood J, Tomlinson E, Bark Y, Kaur K, Johnstone EC, Palles CL, Church DN, Novelli M, Danielsen HE, Sherlock J, Kerr DJ, Kerr R, Sieber O, Taylor JC, Tomlinson I Lancet Gastroenterology and Hepatology 3(9):635-643 02 Jul 2018 Prognostic markers for colorectal cancer: estimating ploidy and stroma H E Danielsen T S Hveem E Domingo M Pradhan A Kleppe R A Syvertsen I Kostolomov J A Nesheim H A Askautrud A Nesbakken DJ Kerr Annals of Oncology, Volume 29, Issue 3, 1 March 2018, Pages 616–623 Andreas Kleppe, Fritz Albregtsen, Ljiljana Vlatkovic, Manohar Pradhan, Birgitte Nielsen, Tarjei S Hveem, Hanne A Askautrud, Gunnar B Kristensen, Arild Nesbakken, Jone Trovik, Håkon Wæhre, Ian Tomlinson, Neil A Shepherd, Marco Novelli, David J Kerr, Håvard E Danielsen. Chromatin organisation and cancer prognosis: a pan-cancer Study. Lancet Oncol 2018; 19: 356–69 Birgitte Nielsen, Andreas Kleppe, Tarjei Sveinsgjerd Hveem, Manohar Pradhan, Rolf Anders Syvertsen, John Arne Nesheim, Gunnar Balle Kristensen, Jone Trovik, David James Kerr, Fritz Albregtsen, Håvard Emil Danielsen; Association Between Proportion of Nuclei With High Chromatin
22
Entropy and Prognosis in Gynecological Cancers,: Journal of the National Cancer Institute, , djy063, https://doi.org/10.1093/jnci/djy063 ,2018 Jonas J. Staudacher1, Jessica Bauer1, Arundhati Jana1, Jun Tian1, Timothy Carroll1, Georgina Mancinelli1, Özkan Özden1, Nancy Krett1, Grace Guzman 2, David Kerr3, Paul Grippo1 & Barbara Jung Activin signaling is an essential component of the TGF-β induced pro-metastatic phenotype in colorectal cancer Nature Scientific Reports | 7: 5569 | DOI:10.1038/s41598-017-05907-8
Orlando , G et al. Variation at 2q35 ( PNKD and TMBIM1 ) influences colorectal cancer risk and
identifies a pleiotropic effect with inflammatory bowel disease. Hum Mol Genet (2016) 25 (11): 2349-2359.
Jarvis, D et al. Mendelian randomisation analysis strongly implicates adiposity with risk of developing
colorectal cancer British Journal of Cancer (2016) 115, 266–272.
Muralee Menon, Chris Cunningham & David Kerr. Addressing unwarranted variations in colorectal
cancer outcomes: a conceptual approach Nature Reviews Clinical Oncology 13, 706–712 (2016)
Richman SD et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal
cancer trials. J Pathol. 238, (4) 562–570, 2016
Purshouse K et al. Whole Genome Sequencing identifies homozygous BRCA2 deletion guiding
treatment in de-differentiated prostate cancer Molecular Case Studies, Published in Advance March 9, 2017, doi 10.1101/mcs.a001362
David J Kerr, Enric Domingo, Rachel Kerr. Is sidedness prognostically important across all stages of colorectal cancer? Lancet Oncology Volume 17, No. 11, p1480–1482, November 2016
Dr Rachel S Kerr, FRCP(UK), Sharon Love, BSc, Eva Segelov, FRACP, Elaine Johnstone, PhD, Beverly
Falcon, PhD, Peter Hewett, FRACS, Andrew Weaver, MD, David Church, MRCP, Claire Scudder, MSc, Sarah Pearson, BSc, Patrick Julier, MSc, Prof Francesco Pezzella, MD, Prof Ian Tomlinson, FRCPath,
Enric Domingo, PhD, David J Kerr, (2016) Adjuvant capecitabine plus bevacizumab versus
capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial Lancet Oncology, Volume 17, No. 11, p1543–1557, November 2016
Al-Tassan,NA et al, (2015)A new GWAS with 1000 genomes imputation identifies novel risk variants
for colorectal cancer. Scientific Reports, 5:10442 Rosmarin D1, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, Domingo E, Jones A, Howarth K,
Freeman-Mills L, Johnstone E, Wang H, Love S, Scudder C, Julier P, Fernández-Rozadilla C, Ruiz-Ponte C, Carracedo A, Castellvi-Bel S, Castells A, Gonzalez-Neira A, Taylor J, Kerr R, Kerr D,
Tomlinson I (2014) A candidate gene study of capecitabine-related toxicity in colorectal cancer
identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. Mar 19 [Epub ahead of print]
Maryam A. Hamdollah Zadeh, Elianna M. Amin, Coralie Hoareau-Aveilla, Enric Domingo, Kirsty E.
Symonds, Xi Ye, Katherine J. Heesom, Andrew Salmon, Olivia D'Silva, Kai B. Betteridge, Ann C. Williams, David J. Kerr, Andrew H.J. Salmon, Sebastian Oltean, Rachel S. Midgley, Michael R.
Ladomery, Steven J. Harper, Alexander H.R. Varey, David O. Bates.
Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance J Molecular Oncology.2014.07.017
Church D, Kerr R, Domingo E, Rosmarin D, Palles C, Maskell K, Tomlinson I, Kerr D. 'Toxgnostics': an
unmet need in cancer medicine. Nat Rev Cancer. 2014 Jun;14(6):440-5.
23
Dan Rosmarin et al Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based
Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis Dan Rosmarin, J Clinical Oncology Apr 1, 2014:1031-1039;
David J. Kerr & Yuankai Shi Biological markers: Tailoring treatment and trials to prognosis Nature
Reviews Clinical Oncology 10, 429-430 (August 2013)
Enric Domingo, David N. Church⇑, Oliver Sieber, Rajarajan Ramamoorthy, Yoko Yanagisawa, Elaine
Johnstone, Brian Davidson, David J. Kerr, Ian P.M. Tomlinson and Rachel Midgley Evaluation
of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer, J Clinical Oncology, 2013:4297-4305
Huijbers A, Tollenaar RAEM, Pelt GWV, Zeestraten ECM, Dutton S, McConkey CC, Domingo E, Smit
VTHBM, Midgley R, Warren BF and Kerr DJ The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients:
Validation in the victor trial Annals of Oncology 24(1):179-185 2013
Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, Pulker H, Lockstone H, Hveem
T, Cranston T, Danielsen H, Novelli M, Davidson B, Xu ZZ, Molloy P, Johnstone E, Holmes C, Midgley
R, Kerr D, Sieber O, Tomlinson IUse of multivariate analysis to suggest a new molecular classification
of colorectal cancer. J Pathol 229(3):441-448 Feb 2013
Mouradov D1, Domingo E, Gibbs P, Jorissen RN, Li S, Soo PY, Lipton L, Desai J, Danielsen HE, Oukrif
D, Novelli M, Yau C, Holmes CC,Jones IT, McLaughlin S, Molloy P, Hawkins NJ, Ward R, Midgely
R, Kerr D, Tomlinson IP, Sieber OM. Survival in stage II/III colorectal cancer is independently
predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J
Gastroenterol. 2013 Nov;108(11):1785-93.
Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Almeida EG,
Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, Barclay E,
Gorman M, Martin L, Kovac MB, Humphray S, The CORGI Consortium, Thomas HJ, Maher E, Evans G,
Lucassen A, Cummings C, Stevens M, Walker L, Halliday D, Armstrong R, Paterson J, Hodgson S,
Homfray T, Side L, Izatt L, Donaldson A, Tomkins S, Morrison P, Goodman S, Brewer C, Henderson A,
Davidson R, Murday V, Cook J, Haites N, Bishop T, Sheridan E, Green A, Marks C, Carpenter S,
Broughton M, Greenhalge L, Suri M, The WGS500 Consortium, Steering Committee:, Donnelly P, Bell
J, Bentley D, McVean G, Ratcliffe P, Taylor J, Wilkie A, Operations Committee:, Donnelly P, Broxholme
J, Buck D, Cazier JB, Cornall R, Gregory L, Knight J, Lunter G, McVean G, Taylor J, Tomlinson I, Wilkie
A, Sequencing & Experimental Follow-up:, Buck D, Gregory L, Humphray S, Kingsbury Z, Data
Analysis:, McVean G, Donnelly P, Cazier JB, Broxholme J, Grocock R, Hatton E, Holmes CC, Hughes L,
Humburg P, Kanapin A, Lunter G, Murray L, Rimmer A, Lucassen A, Holmes CC, Bentley D, Donnelly
P, Taylor J, Petridis C, Roylance R, Sawyer EJ, Kerr DJ, Clark S, Grimes J, Kearsey SE, Thomas HJ,
McVean G, Houlston RS, Tomlinson I Germline mutations affecting the proofreading domains of POLE
and POLD1 predispose to colorectal adenomas and carcinomas.
Nat Genet 45(2):136-144 23 Dec 2012
Beggs AD, Domingo E, McGregor M, Presz M, Johnstone E, Midgley R, Kerr D, Oukrif D, Novelli M,
Abulafi M, Hodgson SV, Fadhil W, Ilyas M, Tomlinson IP Loss of expression of the double strand break
repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70
expression is associated with CIN.
Oncotarget 3(11):1348-1355 Nov 2012
24
Schmoll HJ, Van cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, Van de
Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D,
Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky
G, Douillard JY, El ghazaly H, Gallardo J, Garin A, Glynne-jones R, Jordan K, Meshcheryakov A,
Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A Esmo consensus guidelines for
management of patients with colon and rectal cancer. A personalized approach to clinical decision
making Annals of Oncology 23(10):2479-2516 2012
Kennedy RH, Francis A, Dutton S, Love S, Pearson S, Blazeby JM, Quirke P, Franks PJ, Kerr DJ
EnROL: A multicentre randomised trial of conventional versus laparoscopic surgery for colorectal
cancer within an enhanced recovery programme
BMC Cancer 12 2012
Kinnersley B, Migliorini G, Broderick P, Whiffin N, Dobbins SE, Casey G, Hopper J, Sieber O, Lipton L,
Kerr DJ, Dunlop MG, Tomlinson IP, Houlston RS The TERT variant rs2736100 is associated with
colorectal cancer risk
British Journal of Cancer 107(6):1001-1008 2012
La Thangue, NB and Kerr DJ. Predictive biomarkers: a shift towards personalised cancer medicine Nature Reviews Clinical Oncology 8, 587-596,.2011
Kerr,DJ and Young AM. Targeted therapies:Bevacizumab – has it reached its final resting place? Nature Reviews Clinical Oncology 8, 195-196 , 2011
J Hecht, T Trarbach, J Hainsworth, P Major, E Jager, R Wolff, K Lloyd-Salvant, G Bodoky, K
Pendergrass, W Berg, B Chen, T Jalava, G Meinhardt, D Laurent, D Lebwohl, and D Kerr. A Randomized, Placebo-Controlled, Phase III Study of First-line Oxaliplatin-Based Chemotherapy Plus
PTK787/ZK 222584 (Vatalanib), an Oral VEGF Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma J Clin Oncol, 2011:1997-2003
Tie J1, Lipton L, Desai J, Gibbs P, Jorissen RN, Christie M, Drummond KJ, Thomson BN, Usatoff
V, Evans PM, Pick AW, Knight S,Carne PW, Berry R, Polglase A, McMurrick P, Zhao Q, Busam D, Strausberg RL, Domingo E, Tomlinson IP, Midgley R, Kerr D, Sieber OM.
KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal
cancer. Clin Cancer Res. 2011 Mar 1;17(5):1122-30.
Niedzwiecki D, Bertagnolli M, Warren S, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts
SR, Porjosh GN , Kerr DJ, Fields, Goldberg< Mayer R, Colaccio TA Documenting the natural historyof patients with resection of stage2 adenocarcinoma of the colon after randomisation to Edrocolomab or
observation. . J Clin Oncol , 11, 2011:3146-3152
Quirke P, Hutchins G, Southward K, Hardley K, Magill L, Beaumont C, Stahlschmidt J, Rickman S,
Chambers P, Seymour M, Gray R and Kerr DJ. Value of mismatch repair, KRAS and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol,
2011:1261-1270
Salazar R, Roepman P, Capella G, Moreno V, Simon I, López-Doriga1 A, Marijnen C, Westerga J,
Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, M Glas A, Van ’t Veer L and Tollenaar R. A Gene Expression Signature to Improve Prognosis Prediction of Stage II and III
Colorectal Cancer J Clin Oncol, 1,2011:17-24
25
Gray R, Quirke P, Hardley K, Lopatin M, Magill L, aehner FL, Beaumont C, Clark-Langore KM, Yoshiwarza CN, Lee M, Watson D, Shak S and Kerr DJ. Validation Study of a Quantitative multi-gene
RT-PCR assay as a predictor of recurrence in stage II colon cancer patient. J Clin Oncol, 12,2011:4611-4619
Houlston R, Cheadle J, Dobbins S, et al. Meta-analysis of three UK genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature
Genetics, 42,973-77,2010.
Chen l, Zeng X, Wang J, Briggs SS, O’Neil E, Li J, Leek R, Kerr DJ, Harris AL, Cai L . Roles of
Tetrahydrobiopterin in promoting tumour angiogenesis. Am J Pathol 2010 , 179: 2671-2680
Midgley RS, McConkey C, Kerr DJ et al. Final Results of the VICTOR Trial: A Phase III Randomized Trial
Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer. J Clin Oncol, 4575-4580, 2010.
Kerr DK and Midgley R. Defective Mismatch Repair in Colon Cancer: A prognostic or predictive
biomarker? – Journal of Clinical Oncology, 3210-3212, 2010
The International Cancer Genome Consortium. Sequencing the cancer genome. Nature 2010 Apr 15;464(7291):993-8.
Kerr SH, Kerr DJ. Novel treatments for hepatocellular cancer. Cancer Letters 286 (2009) 114–120
Al-Salama H, Johnstone E and Kerr DJ. What Is the Role and Impact of Molecular Markers on
Treatment Decisions for Colorectal Cancer in the Adjuvant Setting? Discovery Medicine. 2009. Discovery Medicine, volume 8, number 42, Pages 104-107.
Kerr DJ and Kakil IR. Targeted therapies: Cetuximab plus chemotherapy in patients with advanced
cancer. Nature Reviews Clinical Oncology. 2009 Sep;6(9):499-500
Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr DJ. Genetic prognostic and
predictive markers in colorectal cancer. Nature Reviews Cancer, 2009, 9: 489-499.
Robert N. Jorissen, Peter Gibbs, Michael Christie, Saurabh Prakash, Lara Lipton, Jayesh Desai, David
Kerr, Lauri A. Aaltonen, Diego Arango, Mogens Kruhøffer, Torben F. Ørntoft, Claus Lindbjerg
Andersen, Mike Gruidl, Vidya P. Kamath, Steven Eschrich, Timothy J. Yeatman and Oliver M. Sieber. Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage
B and C Colorectal Cancer Clin Cancer Res December 15, 2009 15:7642-7651;
Luis S, Spain S, Tomlinson I, Kerr D; Houlston R, Cazier J. Common variation at the Adiponectin locus is not associated with colorectal cancer risk in the United Kingdom. Human Molecular Genetics,
18, 1889-1892, 2008.
Midgley RS, Yanagisawa Y, Kerr DJ. Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol. 2009 Feb;6(2):108-20.
Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O’Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, De Gramont A, for the Adjuvant
Colon Cancer Endpoints (ACCENT) Group16. Evidence for cure by adjuvant therapy in colon cancer: Observations Based on Individual Patient Data from 20,898 Patients of 18 Randomized Trials. : J Clin
Oncol. 2009 Feb 20;27(6):872-7.
26
Midgley R, Kerr DJ. Capecitabine: have we got the right dose? Nature Clinical Practice. Vol 6: 1,
17-24. Oct 2008.
Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven N, Kerr DJ, Young LS,
Adams DH. 3A Phase II Study of Adoptive Immunotherapy Using Dendritic Cells Pulsed with Tumor
Lysate in Patients with Hepatocellular Carcinoma. Hepatology. 2009 Jan;49(1):124-32.
Popov I, Carrato A, Sobrero A, Vincent M, Kerr D, Labianca R, Raffaele Bianco A, El-Serafi M, Bedenne L, Paillot B, Minik, Evaristo E. Raltitrexed (Tomudex_) versus standard leucovorin-
modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in
Adjuvant Colon Cancer 01 (PETACC-1). 2008. European Journal of Cancer, 44, 2004-2211.
Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset J-F, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD,
Moore M, Nordlinger B, Rougier R, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, Tempero M, Van De Velde C, Zalcberg J. The diagnosis and management of rectal cancer. Expert discussion
and recommendations derived from the 9th world congress on gastrointestinal cancer, Barcelona,
2007. Annals of Oncology. 19 (supplement 6): vii1-vi8, 2008
Kerr DJ. Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment. Nature Clinical Practice Oncology. Vol 5, 250-251.2008
Cogent Study Group Meta-analysis of genome-wide association data identifies four new susceptibility
loci for colorectal cancer. Nat Genetics 40, 1426-35,2008
Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman A, Spain S , Lubbe S, Walther A, Sullivan K, Jaeger E, Fielding S, Rowan A, Vijayakrishnan J, Domingo E, Chandler I,
Kemp Z, Qureshi M, Farrington S, Tenesa A, Prendergast J, Barnetson R, Penegar S, Barclay E, Wood W, Martin L, Gorman M, Thomas H, Peto J, Bishop T, Gray R, Maher E, Lucassen A, Kerr D, Evans E,
The CORGI Consortium, Schafmayer C, Buch S, Izke H, Hampe J, Schreiber S, John U, Koessler T, Pharoah P, van Wezel T, Morreau H, Wijnen J, Hopper J, Southey M, Giles G, Severi G, Castellvı´-Bel
S, Ruiz-Ponte C, Carracedo A, Castells A, The EPICOLON Consortium, Fo¨rsti A, Hemminki K,
Vodicka P, Naccarati A, Lipton L, WC Ho J, Cheng K, Sham P, Luk J, Agu´ ndez J , Ladero J, de la Hoya M, Calde´s T, Niittyma¨ki I, Tuupanene S, Karhu A, Aaltonen L, CazierJB, Campbell H, Dunlop
M, & Houlston R. A genome-wide association study identifies novel colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics. 40, 623-630. 2008.
Jaeger E, Webb E, Howart K, Carvajal-Carmona L, Rowan A, Broderick P, Walther A, Spain S, Pittma A, Kemp Z, Sullivan K, Heinimann K, Lubbe, Domingo E, Barclay E, Martin L, Gorman M, Chandler I,
Vijayakrishna J, Wood, Papaemmanuil E, Penegar S, Qureshi M, members of the CORGI consortium,
Tenesa A, Cazier JB, Kerr D, Gray R, Peto P, Dunlop M, Thomas HH, Houlston R, Tomlinson I. Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal
cancer risk. Nature Genetics, 40: 26-28, 2007.
Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, Lubbe S, Spain S,
Sullivan K, Fielding S, Jaeger E, Vijayakrishnan J, Kemp Z, Gorman M, Chandler I, Papaemmanuil E, Penegar S, Wood W, Sellick G, Qureshi M, Teixeira A, Domingo E, Barclay E, Martin L, Sieber O, Kerr
D, Gray R, Peto J, Cazier JP, Tomlinson I, Houlston R. A genome-wide association study shows that common alleles of : SMAD7: influence colorectal cancer risk. Nature Genetics 39, 1315 - 1317 (14
Oct 2007).
Sabharwal A and Kerr D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting:
past, present and future. Expert Review Anticancer Therapy. 7 (4), 477-487, 2007.
27
Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore
M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll H, Tabernero J, Tempero M, Van De Velde C, Van Laethem JL, Zalcberg J. The management of pancreatic cancer. Current expert
opinion and recommendations derived from the 8th world congress on gastrointestinal cancer,
Barcelona, 2006. Annals of Oncology. 18 (supplement 7): vii1-vii10, 2007.
Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Francois Seitz J, O'callaghan CJ, Francini G, Grothey A, O'connell M, Catalano PJ, Kerr D, Green E, Wieand HS,
Goldberg RM, Gramont AD. End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18
Randomized Trials From the ACCENT Group. J Clin Oncol. 29: 4569-4574, 2007.
Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I,
Gorman M, Wood W, Barclay E, Lubbe S, Martin L, Sellick G, Jaeger E, Hubner R, Wild R, Rowan A, Fielding S, Howarth K, Silver A, Atkin W, Muir K, Logan R, Kerr D, Johnstone E, Sieber O, Gray R,
Thomas H, Peto J, Cazier JB, Houlston R. A genome-wide association scan of tag SNPs identifies a
susceptibility variant for colorectal cancer at 8q24.21. Nature Genetics 39, 984-988 (01 Aug 07)
Kerr DJ, Dunn JA, Langman MD, Smith JL, Midgley RJ, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC. Rofecoxib and Cardiovascular adverse events in adjuvant treatment of
colorectal cancer. New England Journal of Medicine, 357:360-9. July 2007
Gray, R, Barnwell J, McConkey C, Williams N and Kerr, DJ. QUASAR: a randomised study of adjuvant chemotherapy versus observation including 3239 colorectal cancer patients QUASAR Collaborative
Group. Lancet, 370(9604):2020-9. 2007
Kerr David J. Does chemotherapy given directly to the liver improve survival in patients with hepatic
metastasis? Nature Clinical Practice Oncology 3, 480 – 481. 2006.
Shimizu, Maruta F, Akita N, Miwa S, Seymour L, Kerr, D, Parker A, Miyagawa S. Identification of an oligopeptide binding to Hepatocellular carcinoma. Oncology 941. 2006
Russo, A, Bazan V, Iacopetta B, Kerr, D, Sonssi T, Gebbia N. The TP53 Colorectal Cancer
International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumour Site, Type of Mutation, and Adjuvant Treatment. Journal of Clinical
Oncology. 23: 2005, 7518-7528.
Sargent DJ, Wieand HS, Haller D G, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O’Callaghan CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T,
Goldberg RM, De Gramont A. Disease-free survival versus overall survival as a primary end point of
adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomised trials. Journal of Clinical Oncology. 2005, 23, No 34: pp. 8664-8670
Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit
JM, Steven N, Bakker JM, Semiond D, Kerr DJ, Punt CJ. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann
Oncol. 2005 Jul;16(7):1123-32. Epub 2005 Jun 6.
Neoptolemos J. P., Stocken D. D., Friess H., Bassi C., Dunn J. A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D. J., Büchler M.
W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
New England Journal of Medicine. 350; 12. March 2004.
28
Chan, R and Kerr DJ. Can we individualise chemotherapy for colorectal cancer? Annals of Oncology.
15, 996-999, July 2004
Kerr D and Van Cutsem E. New approaches for the treatment of colorectal cancer in the adjuvant setting. Eur J Cancer. Vol 2 No 7, 34-39. 2004
Grabsch H, Kerr D and Quirke P. Is there a case for routine clinical application of ploidy measurements in gastrointestinal tumours?. Histopathology. 45, 312-334. 2004
Kerr D. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nature Clinical
Practice, Oncology. Vol 1, 39-43, 2004
Kerr DJ. Clinical development of gene therapy for colorectal cancer. Nature Reviews Cancer, (2003)
3 615-622.
Grumett, SA and Kerr DJ. Irinotecan and Capecitabine in a patient with advanced colorectal cancer. Case Studies in Colorectal Cancer. (August 2003), Vol2, No.5.
Nicum S, Midgley R, Kerr DJ. Colorectal cancer. Acta Oncol. 2003;42(4):263-75.
Kerr, D.J., McArdle, C.S; Ledermann, J; Taylor, I; Sherlock, S.J; Schlag, P.M; Buckels, J; Mayer, D; Cain,
D; Stephens, R.J. Intrahepatic arterial versus intravenous 5 fluorouracil and leucovorin for colorectal
cancer liver metastases: results of a multicentre randomised trial, Lancet, 2003, 361,368-373
Midgley, RS; Kerr, D.J. Immunotherapy for colorectal cancer. Expert Rev. Anticancer Ther. 3(1), 63-78, 2003.
Maughan TS, James RD, Kerr D, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D, Stephens RJ on behalf of the MRC Colorectal Cancer Group Comparison of intermittent and continuous palliative
chemotherapy for advanced colorectal: a multicentre randomized trial. Lancet, 2003;361:457-64
Hosie KB, Kerr DJ, Gilbert JA, Downes M, Lakin G, Pemberton G, Timms K, Young A and Stanley A. A
Pilot study of adjuvant intraperitoneal 5-fluororuarcil using 4% icodextrin as a novel carrier solution. European Journal of Surgical Oncology. (2003) 29: 254-260
Pendlebury S, Duchesne F, Reed K, Smith JL and Kerr DJ. A trial of adjuvant therapy in colorectal
cancer: The VICTOR Trial. Clinical Colorectal Cancer. (2003) Vol 3:1. 58-60
Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Johnston P, Kerr
D, Koehne CH, Labianca R, Minsky B, Nordlinger B, Roth A, Rougier P and Schmoll HP. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference:
Perspectives in Colorectal Cancer, Dublin 2001) European Journal of Cancer. 2002, 38, 1429-1436.
Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P,
Johnston C, Stephens RJ. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002, 359, 1555-1563
Midgley RS, Kerr DJ (2002) Ras as a target in Cancer Therapy. Critical Reviews in Haematology
and Oncology 44(2):109-120
Tebutt NC, Cattell E, Midgley RS, Cunningham D, Kerr DJ. (2002) Systemic therapy of colorectal cancer.
Eur.J.Oncol. 38(7): 1000-1015
Nicum S, Midgley RS, Kerr DJ (2002) Chemotherapy and Radiotherapy for Colorectal Cancer. In:Recent Advances in Coloproctology-Volume 2. In press
29
Kerr, D.J.,and Midgley, R.S. (2002). Immunotherapy for colorectal cancer: potential application in an adjuvant setting. Semin Oncol 27, 132-7.
Hussain, S.A., Ferry, D.R., El-Gazzas, G., Mirza, D.F., James, N.D., McMaster, P., and Kerr, D.J. (2001).
Hepatocellular carcinoma. Ann Oncol 12, 161-72.
Kerr DJ. A United Kingdom Coordinating Committee on Cancer Research Study of Adjuvant
Chemotherapy for Colorectal Cancer: Preliminary Results. Seminars in Oncology, 28(1): 31-34 (2001)
Hosie K, Gilbert JA, Kerr D, Brown CB, Peers EM. Fluid Dynamics in Man of an Intraperitoneal Drug
Delivery Solution: 4% Icodextrin. Drug Delivery, 8: 9-12 (2001).
Neoptolemos JP, Dunn JA, Moffitt DD, Almond J, Link K, Beger H, Bassi C, Pederzoli P, Dervenis C,
Fernandez-Cruz L, Lacaine F, Spooner D*, Kerr DJ*, Friess H, Buchler M. European Study Group for Pancreatic Cancer-1 interim results: a European randomized study to assess the roles of adjuvant
chemotherapy and chemoradiation in resectable pancreatic cancer. British Journal of Surgery
2001;88(3):475-
Neoptolemos, J.P; Dunn,J.A; Stocken,D.D; Almond,J; Link,K; Beger,H; Bassi,C; Falconi,M; Pederzoli,P;
Dervenis,C; Fernandez-Cruz,L; Lacaine,F; Pap,A; Spooner,D; Kerr,D.J; Friess,H; Buchler,M.W. Adjuvant
chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. European-Study-Group-for-Pancreatic-Cancer. Lancet. 2001 Nov 10; 358(9293): 1576-85
Snow,P.B; Kerr,D.J; Brandt,J.M; Rodvold, D.M Neural network and regression predictions of 5-year
survival after colon carcinoma treatment. Cancer. 2001 Apr 15; 91: 1673-8
Grumett,S.A; Archer,V.R; Midgley,R; Mulholland,P; Nicum,S; Blewitt,L; Kerr,D.J. The role of mitomycin
C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy. Ann-Oncol. 2001 Apr; 12(4): 575
Kerr, D.J. Two cultures or two faces? Ann-Oncol. 2001 Jan; 12(1): 7-8
Young,A.M; Kerr,D.J. Home delivery: chemotherapy and pizza? British Medical Journal. 2001 Apr 7; 322(7290): 809-10
Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised
trials. Lancet. 2001; 358:1291-1304
Gray RG, Kerr DJ, McConkey CC, et al. On behalf of QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for
colorectal cancer: a randomised trial. The Lancet, 355, 1588-96 (2000)
Midgley RS, Kerr DJ. Towards post-genomic investigation of colorectal cancer. Lancet, Feb 26; 355
(9205): 669-70 (2000)
Sobrero A, Kerr D, Glimelius B, Van Cutsem E, Milano G, Pritchard DM, Rougier P, Aapro M. New directions in the treatment of colorectal cancer: a look to the future. European Journal of Cancer,
36, 559-566 (2000)
Nicum S, Midgley RS, Kerr DJ. Chemotherapy of colorectal cancer. Journal of the Royal Society of
Medicine, 93, 416-419 (2000)
30
Midgley, R, Kerr D. Immunotherapy for colorectal cancer: a challenge to clinical trial design. The
Lancet, 159-168 (2000)
Chung-Faye, G.A.,and Kerr, D.J. (2000). ABC of colorectal cancer: Innovative treatment for colon cancer. British Medical Journal 321, 1397-9.
Midgley, R.S. and Kerr, D.J. (2000). ABC of colorectal cancer: adjuvant therapy. British Medical Journal 321, 1208-11.
Kerr DJ, Gray R, McConkey C, Barnwell J. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and
levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group. Annals of Oncology
2000;11(8):947-955
Kerr, D.J., Midgley, R.J., and McArdle, C.S. (2000). Hepatic arterial chemotherapy; Still on trial. Journal
of Clinical Oncology 18, 1806-1807.
Kerr, D.J. (1999). Cost of treating colorectal cancers. European Journal of Cancer 35, 187.
Midgley R, Kerr D, Seminar on Colorectal Cancer. Lancet Vol. 353: 391-99 (1999)
Koehne CH, Midgley R, Seymour M, Kerr DJ. Advanced colorectal cancer: which regimes should we
recommend? Annals of Oncology Aug; 10(8):877-82 (1999)
Ingleby, S., Barnwell, J., Baker, J.,Harvey, P., kerr, D.J., Law, V., and Young, A. (1999). A pilot study of a feasibility and economic analysis of home based chemotherapy in advanced colorectal cancer.
European Journal of Cancer 35, 214.
Jessop, J.M., Snow, P., Brandt, J., Bellucco, C., Menck, H.R., and Kerr, D.J. (1999). Artificial neural
network prediction of 5-year survival from colon cancer. European Journal of Cancer 35, 211.
Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS. Molecular Evolution of the Metaplasia-Dysplasia-Adenocarcinoma sequence in the esophagus.
American Journal of Pathology Vol. 154 (4) (1999)
Langman MJS, Dunn JA, Whiting JL, Burton A, Hallissey MT, Fielding JWL, Kerr DJ. Prospective, double-
blind, placebo-controlled randomised trial of cimetidine in gastric cancer. British Journal of Cancer, 81(8), 1356-1362 (1999)
Howell JD, Warren HW, Anderson JH, Kerr DJ, and McArdle CS. Intra-arterial 5-fluorouracil and
intravenous folinic acid in the treatment of liver metastases from colorectal cancer. European Journal of Surgery 1999; Vol 165.652-8.
Young AM, Kerr DJ Novel Treatments for Colorectal Cancer, Oncology Today – 1999 18-26
Young AM, Daryanani S, and Kerr DJ. Can pharmacokinetic monitoring improve clinical use of
fluorouracil? Clinical Pharmacokinetics 1999; 36.391-8.
Ingleby, S., Baker, J., Young, A., and Kerr, D.J. (1999). Health economics analysis of home based vs.
hospital based chemotherapy: Discussion of results. British Journal of Cancer 80, 332.
31
Kerr, D. (1999). Safety of Raltitrexed. Lancet 354, 1825.
Kerr DJ, Ferry DR, Novel therapeutic strategies for colorectal cancer. Hospital Medicine, Vol. 59, No. 8: 617-621, (1998)
Cocconi G, Cunningham, D, Van Cutsem E, Francois E, Gustavsson B, van Hasal G, Kerr D, Possinger K, Hietschold SM. Open, randomized , multicenter trial of raltitrexed versus fluorouracil plus high-dose
leucovorin in patients with advanced colorectal cancer. J. Clin. Onc. 16, 9 : 2943-2952, (1998)
Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-
fluorouracil and leucovorin in patients with advanced colorectal cancer is signjificantly associated with gender, increasing age and cycle number. Tomudex International Study Group. European Journal of
Cancer, 34 (12): 1871-5 (1998)
Wils J, Sahmoud T, Sobrero A, Bleiberg H, Ahmedzai S, Blazeby J, Blijham G, Conroy T, Cunningham D, Curran D, Diaz-Rubio E, Ducreux M, Evans J, Glimelius B, Hutchinson G, Kerr D et al. Evaluation of
clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop
organised by the EORTC GITCCG. European Organisation for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Tumori 1998; 84.335-47.
Baker, J., Bleiberg, H., Hutchison, G., Jackman, A., Kerr, D., Labianca, R., Macdonald, J., Meyer, H.J.,
Minsky, B., Nordlinger, B., Rougier, P., Smits, S., Sobrero, A., Taylor, I., and Verweijm J. An international multidisciplinary approach to the management of advanced colorectal cancer (First of two parts)
(Reprinted from Eur J Surg Oncol, Vol 23, Suppl A, August 1997) Annales Chirurgiae Et Gynaecologiae 87, 255-264. (1998).
Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Miller A. Combined Analysis of studies of the effects of the matrix
metalloprote4inase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clinical Cancer Research. Vol. 4: 1101-
1109, May 1998
Seymour LW, Olliff SP, Poole CJ, de Takats PG, Orme R, Ferry DR, Maeda H, Konno T, Kerr DJ. A novel
dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) – neocarzinostatin] in the treatment of primary hepatocellular carcinoma. International Journal of
Oncology 12: 1217-12223, (1998).
Rougier P, Ducreux M, Kerr D, Carr BI, Francois E, Adenis E and Seymour LA Phase II study of
raltitrexed ‘Tomudex’ in patients with hepatocellular carcinoma. Annals of Oncology 8: 500-502 (1997)
Kerr DJ, O’Connor K.M. The costs of managing advanced colorectal cancer: a broad perspective. Anti-
Cancer Drugs Vol. 8, Suppl 2 1997 S23 (1997)
Neoptolemos JP, Kerr DJ, Beger H, Link K, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Laçaine
F, Freiss H, Büchler M. ESPAC-1 Trial Progress Report. The European randomised adjuvant study comparing radiochemotherapy, six months chemotherapy and combination therapy versus observation
in pancreatic cancer. Digestion: 56: 570-577 (1997)
Midgley RS, Kerr DJ. Adjuvant Therapy of Colorectal Cancer. Cancer Treatment Reviews 23:135-
152. (1997)
32
Blesing, CH, Julyan, PJ, Barnwell, JM, Parker, DJ, Mountford, PJ, Kerr, DJ, and Harding LK Quantitative
whole body counter distribution studies of 18f-5 fluorouracil following hepatic arterial and IV infusion. Br. J. Radiology, 32, 14-19 (1996)
Blesing, CH; Kerr, DJ. Intra-hepatic arterial drug delivery. J Drug Targeting 3: 341-347 (1996)
Green, NK, Searle, PF, Young, LS, Kerr, DJ and Neoptolamos JP Gene Therapy for gastrointestinal cancer, GI Cancer, 2, 43-53 (1996)
De Takats, PG and Kerr DJ Is intra-arterial chemotherapy worthwile in the treatment of patients with
unresectable hepatic colorectal cancer metastases? Eur.J.Cancer 32 13, 2195-2205 (1996)
Kerr, DJ, Young, AM, Neoptolamos, JP, Sherman, J, Van-Geere, P, Stanley, A, Ferry, D, Dobbie, JW,
Vincke, B, Gilbert, J, Dombros, N, and Fountzilos, G.. Prolonged Introperitoneal infusion of 5-FU using a novel carrier solution. Brit. J. Cancer, 74, 2032-2035 (1996)
McArdle, CS; Anderson, JH; Warren, H; Doughty, J; Kerr, DJ. Intra-arterial 5-FU modulated by folinic
acid for colorectal liver mets.Regional Cancer Treat. 9: 27-29 (1996)
Kerr, DJ. Tomudex ZD 1694, a new direct and specific thymidylate synthase inhibitor, has resource saving implications in the management of colorectal cancer. Quality of Life Research 4 6: 576
(1995)
Kerr, DJ; de Takats, PG Chemotherapy for gastrointestinal cancer: teaching old drugs new tricks. GI
Cancer 1: 3-7 (1995)
Kerr, DJ; Ledermann, JA; McArdle, CS; Buckels, J; Neoptolemos, J; Seymour, M; Doughty, J; Budden,
J; Taylor, I. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. J Clin Oncol 1312: 2968-2972 (1995)
Kerr, DJ; Rustin, GJ; Kaye, SB; Selby, P; Bleehen, NM; Harper, P; Brampton, MH.Phase II trials of
rhizoxin in advanced ovarian, colorectal and renal cancer. Br J Cancer 72: 1267-1269 (1995)
Cunningham, D; Zalcberg, JR; Rath, U; Olver, I; Van Cutsem, E; Svensson, C; Seitz, JF; Harper, P; Kerr,
D; Perez-Mango, G; Azab, M; Seymour, L; Lowery, K & the ‘Tomudex’ Colorectal Cancer Study Group Tomudex ZD1694: Results of a randomised trial in advanced colorectal cancer demonstrate efficacy
and reduced mucositis and leucopenia. Eur J Cancer 31A 12: 1945-1954 (1995)
Jodrell, DI; Oster, W; Kerr, DJ; Canney, PA; Yosef, H; Steward, WP; Kaye, SB; Cassidy, J. A phase I/II
study of N-phosphonacetyl-L-Aspartic Acid PALA added to 5-Fluorouracil and folinic acid in advanced colorectal cancer. Eur J Cancer 30a 7: 950-954 (1994)
de Takats, PG; Kerr, DJ; Poole, CJ; Warren, HW; McArdle, CS. Hepatic arterial chemotherapy for
metastatic colorectal carcinoma.Br J Cancer 69: 372-378 (1994)
McArdle, CS; Kerr, DJ; O’Gorman, P; Wotherspoon, HA; Warren, H; Watson, D; Vinke, BJ; Dobbie, JW;
El Eini, DID. Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma. Br J Cancer 70: 762-
766(1994)
Warren, HW; Anderson, JH; O’Gorman, P; Kane, E; Kerr, DJ; Cooke, TG; McArdle, CS. A phase II study
of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases. Br J Cancer 70: 677-680 (1994)
Warren, HW; Anderson, JH; O'Gorman, P; Kerr, DJ; Cooke, TG; McArdle, CS. Ambulatory infusion pumps for intrahepatic arterial chemotherapy. Regional Cancer Treat 2: 77-78 (1993)
33
McArdle, CS. Glass yttrium-90 microspheres for patients with colorectal liver metastases. Anderson,
JH; Goldberg, JA; Bessent, RG; Kerr, DJ; McKillop, JH, Stewart, I; Cooke, TG; Radiotherapy and Oncology 25: 137-139. 1992
Anderson, JH; Kerr, DJ; Cooke, TG; McArdle, CS. A phase I study of regional 5-Fluoruracil and systemic
folinic acid for patients with colorectal liver metastases. Br J Cancer 65: 913-915. 1992
Anderson, JH; Kerr, DJ; Setanoians, A; Cooke, TG; McArdle, CS. A pharmacokinetic comparison of
intravenous versus intra-arterial folinic acid.Br J Cancer 65: 133-135. 1992
Kaye, SB; Brampton, M; Harper, P; Smyth, J; Kerr, DJ; Gore, M; Green, JA; Gilby, E; Crawford, SM; Rustin, GJ. Phase II trials of fosquidone, GR63178A in colorectal, renal and non-small cell lung cancer.
Br J Cancer 65: 624-625. 1992
Kerr, DJ 5-fluorouracil and folinic acid - interesting biochemistry or effective treatment?Brit J Cancer 60 6: 807-809. 1989
34
Section 2: Drug Development and Pharmacology
Khan O, La Thangue, Kerr et al. "HR23B is a biomarker for tumour sensitivity to HDAC inhibitor-
based therapy." Proc Nat Acad Science –107(14):6532-7. 2010.
Rahman N M, Davies HE, Salzberg M, Truog P, Midgely R, Kerr D, Clelland C, Hedley EL, Lee YCG,
Davies RJO. Use of lipoteichoic acid-T for pleurodesis in malignant pleural eff usion: a phase I toxicity and dose-escalation study. Lancet Oncology. 2008. 1016/S1470-2045(08)70205-5.
Middleton M, Knox C, Cattell E, Opperman U, Ali R, Auton T, Agarwal R, Anderson D, Sarker D,
Judson I, Osawa T, Harlley J and Kerr DJ. Quinone Oxido-reductase-2-mediated Prodrug Cancer
Therapy. Science Translational Medicine, 2, 420-428, 2010
Edwards AM, Bountra C, Kerr DJ, Willson TM. Open access chemical and clinical probes to support
drug discovery. Nat Chem Biol. 2009 Jul;5(7):436-40
Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Calver H, Lind M, Robbins A, Burtles S, Duncan R and Cassidy J. Phase II studies of polymer-
doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. International Journal of Oncology. 2009 Jun;34(6):1629-36.
Midgley R, Kerr D, Flaherty K, Stevenson JP, Pratap S, Koch K, Smith D, Versola M, Fleming R, Ward C, O'Dwyer P and Middleton M. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Annals of Oncology 2007 18(12):2025-2029.
Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, Duvauchelle T. Single-dose clinical pharmacokinetic studies of gefitinib. Clinical Pharmacokinetics. 2005;44(11):1165-77
Kerr DJ, La Thangue N. Signal transduction blockade and cancer : combination therapy or multi-
targeted inhibitors? Annals of Oncology, 15: 1727-1729, 2004
Danson S, Ferry D, Alkhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G and Ranson M. Phase
I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. British Journal of Cancer. 2085-2091,2004
Knox RJ, Burke PJ, Chen S, Kerr DJ. CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr
Pharm Des. 2003;9(26):2091-104.
Milner AE, Palmer DH, Hodgkin EA, Eliopoulos AG, Knox PG, Poole CJ, Kerr DJ, Young LS. Induction of
apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells. Cell Death Differ 2002;9(3):287-300
Seymour, L.W., Ferry, D.R., Anderson, D., Doran,J, Young, A.M., Kerr, D.J., Hesselwood,S., Julyan,
P.J., Poyner, R. and Burtles, S., Hepatic drug targeting: Phase I evaluation of polymer-bound
doxorubicin J-Clin-Oncol. 2002 Mar 15; 20(6): 1668-76
Taylor,-P-M; Woodfield,-R-J; Hodgkin,-M-N; Pettitt,-T-R; Martin,-A; Kerr,-D-J; Wakelam,M.J. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-
lipoxygenase catalyzed pathway. Oncogene. 2002 Aug 22; 21(37): 5765-72
Mulholland PJ, Ferry DR, Anderson D, Hussain SA, Young AM, Cook JE, Hodgkin E, Seymour LW, Kerr DJ. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Annals of Oncology
2001;12(2):245-248
35
Ferry DR, Deakin M, Baddeley J, Daryanani S, Bramhall S, Anderson DA, Wakelam MJO, Doran J, Pemberton G, Young AM, Buckels J & Kerr DJ. A phase II study of the 5-lipoxygenase inhibitor, CV6504,
in advanced pancreatic cancer: Correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Annals of Oncology, 11, 1165-1170 (2000).
Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D, Christodoulou C, Young AM, Hesslewood S and Kerr DJ. Preliminary clinical study of the distribution of HPMA
copolymers bearing doxorubicin and galactosamine. Journal of Controlled Release 1999; 57.281-90.
Anderson, D., Ferry, D.R., Knox,R.J., Andrews, S.J., Downes, A.J., Kerr, D.J., and Seymour, L.W. (1999).
High-performance chromatographic method for sensitive determination of the alkylating agent CB1954
in human plasma. Journal of Chromatography B 731, 293-298.
Harper, A., Kerr, D.J., Gescher, A., and Chipman, J.K. (1999). Antioxidant effects of isofavonoids and lignans, and protection against DNA oxidation. Free Radical Research 31, 149-160.
Harper A, Kerr DJ, Gescher A and Chipman JK. Antioxidant effects of isoflavonoids and lignans, and protection against DNA oxidation. Free Radical Res., 31, 149-160 (1999)
Murray LS, Jodrell DI, Morrison JG, Cook A, Kerr DJ, Whiting B, Kaye SB, Cassidy J. The effect of
Cimetidine on the pharmacokinetics of Epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clinical Oncology 10:35-38 (1998)
Helsby NA, Chipman JK, Gescher A and Kerr DJ. Inhibition of mouse and human CYP 1A-and 2E1-
dependent substrate metabolism by the isoflavonoids Genistein and Equol. Food and Chemical Toxicology, 36, 375-382 (1998)
Schultze-Mosgau M, Dale IL, Gant TW, Chipman JK, Kerr DJ and Gescher A. Regulation of c-fos
transcription by chemopreventive isoflavonoids and lignans in MDA-MB-468 breast cancer cells. Europ.
J. Cancer,Vol 34 : 9, 1425-1431 (1998)
Helsby NA, Chipman JK, Gescher A and Kerr D. Inhibition of carcinogen-activating cytochrome P450s by potential chemopreventative agents genistein and equol. Food Chem. Toxicol. 36, 568-577
Christodoulou CV, Eliopoulos AG, Young LS, Hodgkins L, Ferry DR and Kerr DJ. Anti-proliferative activity
and mechanism of action of titanocene dichloride. British Journal of Cancer 77(12: 2088-2097
(1998)
Christodoulou CV, Ferry DR, Fyfe DW, Young A, Doran J, Sheehan TMT, Elipoulos A, Hale K, Baumgart J, Sass G, Kerr David J. Phase I Trial of weekly scheduling and pharmacokinetics of titanocene dichloride
in patients with advanced cancer. J. Clin. Oncol 16: 8 2761-2769 (1998)
Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D, Christodoulou
C, Young AM, Hesslewood S Kerr DJ. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. Journal of Controlled Release 57: 281-290 (1998)
Anderson, D; Kerr, DJ; Blesing, C; Seymour, LW Simultaneous gas chromatographic-mass
spectrophotometric determination of a-fluoro-b-alanine and 5-fluorouracil in plasma. J Chromatogr.
688, 87-93 (1997)
36
Helsby NA, Williams, J, Kerr, D, Gescher, A, Chipman, JK. The isoflavones equol and genistein do not
induce xenobiotic-metabolising enzymes in mouse and in human cells.Xenobiotica, Vol. 27, 6: 587-596 (1997)
Cross MJ, Hodgkin MN, Plumb JA, Brunton VG, Stewart A, MacAully G, Hill R, Kerr DJ, Workman P,
Wakelam MJO. Inhibition of phospholipid signalling and proliferation of Swiss 3T3 cells by the
wortmannin analogue demethoxyviridin. Biochimica et Biophysica ACT 1362 29-38 (1997)
Helsby NA, Williams J, Kerr D, Gescher A and Chipman JK. The isoflavones equol and genistein do not induce xenobiotic-metabolising enzymes in mouse and in human cells. Xenobiotica 27, 587-596
(1997)
Seymour, LW; Shoaibi, MA; Martin, A; Ahmal, A; Elvin, P; Kerr, DJ and Wakelam MJO Vascular
endothelial growth factors stimulates protein kinase C dependent phospholipase D activity in endothelial cells. Lab.Invest. 75 3, 427-437 (1996)
Ferry, DR; Smith, A; Malkhandi, J; Fyfe, DW; de Takats, PG; Anderson, D; Baker, J; Kerr, DJ Phase I
trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
Clinical Cancer Res 2: 659-668 (1996)
Eliopoulos AG, Dawson CW, Mosialos G, Floettmann J Eike, Rowe M, Armitage, RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJO, Reed JC, Kieff E and Young LS. CD40-induced growth inhibition in epithelial
cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene (1996) 13, 2243-2254 (1996)
Eliopoulos, AG; Kerr, DJ; Herod, J; Hodgkins, L; Krajewski, S; Reed, JC; Young, LS The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11: 1217-
1228 (1995)
Eliopoulos, AG; Kerr, DJ; Maurer, HR; Hilgard, P; Spandidos, DA. Induction of the c-myc but not the
cH-ras promoter by platinum compounds. Biochem Pharmacol 50 1: 33-38 (1995)
Ferry, DR; Malkhandi, PJ; Russell, MA; Kerr, DJ. Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 49 12: 1851-1861(1995)
Cross, MJ; Stewart, A; Hodgkin, MN; Kerr, DJ; Wakelam, MJO. Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in swiss 3T3 cells. J of Biological Chem,
270 43: 25352-25355 (1995)
Liu, B; Anderson, D; Ferry, DR; Seymour, LW; de Takats, PG; Kerr, DJ.Determination of quercetin in human plasma using reverse-phase high-performance liquid chromatography. J Chromatography
B, 666: 149-155 (1995)
Liu, B; Earl, HM; Poole, CJ; Dunn, J; Kerr, DJ Etoposide protein binding in cancer patients. Cancer
Chemother Pharmacol 36: 506-512 (1995)
Liu, B; Earl, HM; Baban, DF; Shoaibi, M; Fabra, A; Kerr, DJ; Seymour, LW Melanoma cell lines express
VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Comm 217 3: 721-727. (1995)
Ferry, DR; Kerr, DJ Multidrug resistance in cancer. Br Med J 308: 148-149 (1994)
Malkhandi, J; Ferry, DR; Boer, R; Gekeler, V; Ise, W; Kerr, DJ. Dexniguldipine-HCl is a potent allosteric
inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. Eur J Pharmacol Mol.
Pharmacol. Section 288: 105-114 (1994)
37
Wishart GC; Bissett, D; Paul, J; Jodrell, D; Harnett, A; Habeshaw, T; Kerr, DJ; Macham, MA; Soukop,
M; Leonard, RCF, Knepil, J; Kaye, SB Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo controlled randomized trial. J Clin Oncol 12 9: 1771-1777
(1994)
Cross, MJ; Stewart, A; Plumb, J; Mcauley, G; Hill, RA; Isaacs, N; Workman, P; Kerr, D; Wakelam, MJO
Inhibition of phospholipases and cell proliferation by demethoxyviridin. J Cellular Biochem. S18D: 56 (1994)
Kerr, DJ. Phase I clinical trials: adapting methodology to face new challenges. Annals Oncol 5 4:
S67-S70 (1994)
Morrison, JG; Bissett, D; Stephens, IFD; McKay, K; Brown, R; Graham, MA; Fichtinger-Schepman,AM;
Kerr, DJ. The isolation and identification of cis-diamminedichloroplatinum II-DNA adducts by anion exchange HPLC and inductively coupled plasma mass spectrometry. Int J Oncology 2: 33-37 (1993)
Plumb, JA; Luo, W; Kerr, DJ. Effect of polyunsaturated fatty-acids on the drug sensitivity of human
tumour cell lines resistant to either cisplatin or doxorubicin. Br J Cancer 67 4: 728-733 (1993)
Kerr,DJ; Los,G. Ph armacokinetic principles of locoregional chemotherapy. Cancer Surveys 17: 105-
122 (1993)
Bissett, D; Setonoians, A; Cassidy, J; Graham, M; Chadwick, GA; Wilson, P; Auzanet, V; LeBail, N; Kaye, SB; Kerr, DJ. Phase I and pharmacokinetic study of taxotere RP 56976 administered as a 24-hour
infusion. Cancer Res 53: 523-527 (1993)
Cassidy, J; Graham, MA; Huinink, WT; McDaniel, C; Setanoians, A; Rankin, EM; Kerr, DJ; Kaye, SB for
the EORTC ECTG. Phase I clinical study of LL-D49194a1 with retrospective pharmacokinetic investigations in mice and humans. Cancer Chemother Pharmacol 31 5: 395-400 (1993)
Zoumpourlis, V; Kerr, DJ; Spandidos, DA. Differential Interaction of Cisplatin with the HIV-1 long terminal repeat in a resistant ovarian carcinoma cell line. Anti-Cancer Drugs 4: 77-83 (1993)
Dunlop, DJ; Wright, EG; Lawrence, S; Graham, GJ; Holyoake, T; Kerr, DJ; Wolfe, SD; Pragnell, IB.
Demonstration of Stem cell inhibition and myeloprotective effects of SCI/rhMIPIa in vivo. Blood 79 9: 2221-2225. 1992
Bisset, D; Graham, MA; Setanoians, A; Chadwick, GA; Wilson, P; Koier, R; Henrar, R; Schwartsmann,
G; Cassidy, J; Kaye, SB; Kerr, DJ. Phase I and pharmacokinetic study of rhizoxin. Cancer Res 52:
2894-2898. 1992
Wade, JR; Kelman, AW; Kerr, DJ; Robert, J; Whiting, B Variability in the pharmacokinetics of epirubicin : a population analysis. Cancer Chemother Pharmacol 29: 391-395. 1992
Zoumpourlis, V; Kerr, DJ; Spandidos, DA Carboplatin as opposed to cisplatin does not stimulate the
expression of the human immunodeficiency virus long terminal repeat sequences. Biochem
Pharmacol 43 3: 650-654. 1992
Bissett, D; Kaye, SB; Kerr, DJ. Can primary osteosarcoma act as a third space after high dose methotrexate?. Eur J Cancer 27: 1060. 1992
Goldberg, JA; Willmott, N; Kerr, DJ; Sutherland, C; McArdle, CS. An in vivo assessment of adriamycin-loaded albumin microspheres. Br J Cancer 65: 393-395. 1992
Scott, RN; Blackie, R; Kerr, DJ; Hughes, J; Burnside, G; MacKie, RM; Byrne, DS; McKay, AJ Melphalan
concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer 28a 11: 1811-1813. 1992
38
Scott, RN; Kerr, DJ; Blackie, R; Hughes, J; Burnside, G; MacKie, RM; Byrne, DS; McKay, AJ The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J
Cancer. 66: 159-166. 1992
Cassidy, J; Bissett, D; Kerr, DJ. Methodological aspects of phase I studies of novel anti-cancer agents
Review. Int J Oncol 1: 195-199. 1992
Graham, MA; Bissett, D; Setanoians, A; Kerr, DJ. Pre-clinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme. J National Cancer Inst 84: 494-500. 1992
Bissett, D; Kerr, DJ; Cassidy, J; Meredith, P; Traugott, U; Kaye, SB Phase I and pharmacokinetic study
of D-verapamil and doxorubicin. Br J Cancer 64: 1168-1171. 1991
Eliopoulos, A; Kerr, DJ; Spandidos, DA. The effect of doxorubicin, daunorubicin and 4’-epidoxorubicin on the exogenous c-myc promoter in mouse erythroleukaemia cells. Anticancer Res 11: 2153-2158.
1991
Graham, MA; Riley, RJ; Kerr, DJ. Drug metabolism in carcinogenesis and cancer chemotherapy.
Pharmac Ther 51: 275-289. 1991
Kaye, SB; Kerr, DJ. Multidrug resistance : Clinical relevance in haematological malignancies. Blood
Reviews 6: 39-42. 1991
Zoumpourlis, V; Kerr, DJ; Spandidos, DA. Doxorubicin stimulates transcription from the human immunodeficiency virus long terminal repeat sequences. Cancer Letters 56: 181-185. 1991
Goldberg, JA; Kerr, DJ; Blackie, R; Whately, TL; Pettit, L; Kato, T; McArdle, CS.Mitomycin C-loaded microcapsules in the treatment of colorectal liver metastases. Cancer 67: 952-955. 1991
Goldberg, JA; Murray, T; Kerr, DJ; Willmott, N; Bessent, RG, McKillop, JH; McArdle, CS.The use of
angiotensin II as a potential method of targeting cytotoxic microspheres in patients with intrahepatic tumour. Br J Cancer 63: 308-310. 1991
Cytotoxic-loaded microspheres in patients with colorectal liver metastases.Br J Cancer 64: 114-119. 1991
Kerr, DJ; Kaye, SB.Chemoembolism in cancer chemotherapy. Critical Reviews in Therapeutic Drug
Carrier Systems 8 1: 19-37. 1991
Eliopoulos, A; Kerr, DJ; Spandidos, DA The effect of cisplatin and carboplatin on c-myc promoter in
erythroleukaemic cells. Anticancer Drugs 2: 597-601. 1991
Kerr, DJ; Plumb, JA; Freshney, RI; Khan, MZ; Spandidos, DA The effect of H-ras oncogene transfection on response of mink lung epithelial cells to growth factors and cytotoxic drugs. Anticancer Res 11:
1349-1352. 1991
Wishart, GC; Plumb, JA; Spandidos, DA; Kerr, DJ H-ras transfection in mink lung epithelial cells may
induce “atypical” multidrug resistance. Eur J Cancer 27 5: 673. 1991
Anderson, JH; Goldberg, JA; Eley, JG; Whateley, TL; Kerr, DJ; Cooke, TG; McArdle,CS A Phase I study
of regionally administered mitomycin microcapsules for patients with colorectal liver metastases.Eur J Cancer 27 9: 1189-1190. 1991
Thomson, AM; Kerr, DJ; Steel, CM Transforming growth factor b1 is implicated in the failure of
Tamoxifen therapy in human breast cancer. Br J Cancer, 63: 609-614. 1991
39
Jones, RD; Kerr, DJ; Harnett, AN; Rankin, EM; Ray, S; Kaye, SB. A pilot study of quinidine and epirubicin
in the treatment of advanced breast cancer. Br J Cancer 62: 133-135. 1990
Kerr, DJ; Kaye, SB. Multidrug resistance in haematological malignancies. Haematology Reviews 4: 61-64. 1990
Kerr, DJ; Khan, MZ; Plumb, JA; Freshney, RI; Spandidos, DA. The effect of oncogene transfection on epithelial cell response to cytotoxic drugs. Biochem Pharmacol 9: 375-379. 1990
Goldberg, JA; Kerr, DJ; Stewart, I; McArdle, CS. A comparison of regional and systemic chemotherapy
for hepatic metastases.Eur J Surg Oncol 16: 464-467. 1990
Goldberg, JA; Kerr, DJ; Willmott, N; McKillop, J; McArdle, CS. Regional chemotherapy for colorectal liver
metastases : a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases.Br J Surgery 77: 1238-1240. 1990
Carmichael, J; Cantwell, KA; Mannix, KA; Veale, D; Elford, HL; Blackie, R; Kerr, DJ; Kaye, SB; Harris,
AL.A phase I and pharmacokinetic study of didox admistered by 36 hour infusion. Br J Cancer 61:
447-450. 1990
Kerr, DJ; Slack, JA; Secrett, P; Stevens, MFG; Blackledge, GRP; Bradley, C; Kaye, SB. Relationships between the pharmacokinetics and toxicity of mitozolamide. Cancer Chemother Pharmacol 25: 352-
354. 1990
Kerr, DJ; Lewis, C; O'Neil, B; Lawson, N; Blackie, R; Newell, DR; Roball, F; Cox, J; Rankin, EM; Kay, SB
The myelotoxicity of carboplatin is influenced by the time of its administration. Haematol Oncol 8: 54-65. 1990
Goldberg, JA; Kerr, DJ; Watson, DG; Willmott, N; Bates, CD; McKillop, JH; McArdle, CS The
pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic
metastases.Br J Cancer 62: 78-85. 1990
Lewis, C; Lawson, N; Rankin, EM; Morrison, G; MacLean, AB; Cordiner, J; Cassidy, J; Kerr, DJ; Kaye, SB Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian
cancer.Cancer Chemother Pharmacol 26: 283-287. 1990
Cummings, J; Double, JA; Bibby, M; Farmer, P; Evans, S; Kerr, DJ; Kaye, SB; Smyth, JF. Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in
humans and mice. Cancer Res 49: 3587-3593. 1989
Kerr, DJ; Kaye, SB. Flavone acetic acid - preclinical and clinical activity. Eur J Cancer Clin Oncol 25
9: 1271-1272. 1989
Kerr, DJ; Pragnell, IB; Sproul, A; Cowan, S; Murray, T; George, D; Leake, R The cytostatic effects of a-interferon may be mediated by transforming growth factor-b. J Molec Endocrin 2: 131-136. 1989
Kerr, DJ; Maughan, T; Newlands, E; Rustin, G; Bleehen, NM; Lewis, C; Kaye, SB. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer 60: 104-
106. 1989
Kerr, DJ; Hynds, S; Shepherd, J; Packard, CJ; Kaye, SB. Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers.
Biochem Pharmacol 37 20: 3981-3986. 1988
Kerr, DJ; Rogerson, A; Morrison, GJ; Florence, AT; Kaye, SB. Antitumour activity and pharmacokinetics
of niosome encapsulated adriamycin in monolayer, spheroid and xenograft. Br J Cancer 58: 432-436. 1988
40
Kerr, DJ; Wheldon, TE; Hynds, S; Kaye, SB. Cytotoxic drug penetration studies in multicellular tumour spheroids. Xenobiotica, 18 6: 641-648. 1988
Goldberg, JA; Fenner, J; Bradnam, MS; Bessent, RG; McKillop, JH; Kerr, DJ; McArdle, CS.Improved
tumour targeting of biodegradable microspheres with angiotensin II. Br J Surgery 75 12:1262. 1988
Goldberg, JA; Kerr, DJ; Willmott, N; McKillop, JH; McArdle, CS.Pharmacokinetics and
pharmacodynamics of locoregional 5 fluorouracil 5FU in advanced colorectal liver metastases.Br J Cancer 57: 186-189. 1988
Kerr, DJ; Willmott, N; Levi, H; McArdle, CS.The pharmacokinetics and disposition of adriamycin loaded
albumin microspheres following intra renal arterial administration.Cancer 62: 878-882. 1988
McArdle, CS; Lewis, H; Hansell, D; Kerr, DJ; McKillop, J; Willmott, N.Cytotoxic loaded albumin
microspheres : a novel approach to regional chemotherapy.Br. J Surg 75: 132-134. 1988
Gouyette, A; Kerr, DJ; Kaye, SB; Setanoians, A; Cassidy, J; Bradley, C; Forrest, G; Soukop, M. Flavone
acetic acid : a non linear pharmacokinetic model. Cancer Chemother Pharmacol 22: 114-119. 1988
Goldberg, JA; Kerr, DJ; Willmott, N; McArdle, CS; Murray, T; Hilditch, T Increased uptake of radiolabelled microspheres with angiotensin II in colorectal hepatic metastases. Eur J Surgical Oncol
14: 715. 1988
Kerr, DJ; Harding, M; Amarin, J; Farmer, J; Blackie, RG; Kaye, SB The pharmacokinetics of CHIP in
patients with impaired renal function and following intraperitoneal administration.Oncology and Tumour Pharmacotherapy 5 3: 153-158. 1988
Veale, D; Carmichael, J; Cantwell, BMJ; Elford, HL; Blackie, R; Kerr, DJ; Kaye, SB; Harris, AL A phase I
and pharmacokinetic study of didox : A ribonucleotide reductase inhibitor. Br J Cancer 58: 70-72. 1988
Goldberg, JA; Fenner, J; Bessent, RG; Bradnam, MS; McKillop, JH; McKee, RF; McArdle, CS; Kerr,
DJ.Clinical evaluation of angiotensin II enhanced perfusion scintigraphy in metastatic liver disease. Nuclear Med Comm 10: 557-566. 1988
Cummings,-J; Kerr,-D-J; Kaye,-S-B; Smyth,-J-F. Optimisation of a reversed-phase high-performance liquid chromatographic method for the determination of flavone acetic acid and its major human
metabolites in plasma and urine. J-Chromatogr. 1988 Sep 23; 431(1): 77-85
Goldberg, JA; Bradnam, MS; Kerr, DJ; Haughton, DM; McKillop, JH;Bessent, RG; Willmott, N; McArdle, CS; George, WD Arterio-venous shunting of microspheres in patients with colorectal liver metastases:
errors in assessment due to free pertechnetate and the effect of angiotensin II.Nuclear Med Comm 8: 1033-1046. 1987
Goldberg, JA; Bradnam, MS; Kerr, DJ; McKillop, JH; Bessent, RG; McArdle, CS; Willmott, N; George,
WD Single photon emission computed tomographic studies SPECT of hepatic arterial perfusion
scintigraphy HAPS in patients with colo- rectal liver metastases : improved targeting by tumour microspheres with angiotensin II. Nuclear Med Comm 8: 1025-1032. 1987
Cummings, J; Willmott, N; More, I; Kerr, DJ; Lewi, HJ; McKillop, J. Comparitive cardiotoxicity and
antitumour activity of doxorubicin adriamycin and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues. Biochemical Pharmacology 36 9: 1521-1526. 1987
Cummings, J; Kerr DJ; Kaye, SB. Occurrence of circulating 7-deoxyaglycone metabolites of 4'-
deoxydoxorubicin in man. Cancer Chemother Pharmacol 20: 263-264. 1987
41
Kerr, DJ; Kaye, SB; Cassidy, J; Bradley, C; Rankin, EM; Adams, L; Setonoians, A; Young, T; Forrest, G;
Soukop, M; Clavel, M. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 47: 6776-6781. 1987
Cummings, J; Kerr, DJ; Kaye, SB Occurrence of circulating 7-deoxyaglycone metabolites of 4'-
deoxydoxorubicin in man. Cancer Chemother Pharmacol 20: 263-264. 1987
Cummings, J; Willmott, N; More, I; Kerr, DJ; Gilmour, J; Morrison, JG; Kaye, SB.Comparative cardiotoxicity and antitumour activity of doxorubicin adriamycin and 4'-deoxydoxorubicin and the
relationship to in vivo disposition and metabolism in the target tissues.Biochem Pharmacol 36 9:
1521-1526. 1987
Kerr, DJ.Microparticulate vehicles as cytotoxic drug carriers. Cancer Drug Delivery 4 1: 55-60. 1987
Kerr, DJ; Kaye, SB.Aspects of cytotoxic drug penetration, with particular reference to anthracyclines.Cancer Chemother Pharmacol 19: 1-5. 1987
Kerr, DJ; Kerr, AM; Wheldon, TE; Kaye, SB.In vitro chemosensitivity testing using the multicellular tumour spheroid model. Cancer Drug Delivery 4 2: 124-130. 1987
Kerr, DJ; Wheldon, TE; Russell, JG; Maurer, HR; Florence, AT; Halbert, GW; Freshney, RI; Kaye, SB.The
effect of the non-ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer, spheroid and clonogenic culture systems. Eur J Cancer Clin. Oncol. 23 9: 1315-1322. 1987
Kerr, DJ; Wheldon, TE; Kerr, AM; Freshney, RI; Kaye, SB. The effect of adriamycin and 4'-deoxydoxorubicin on cell survival on human lung tumour cells grown in monolayer and as spheroids.
Br J Cancer, 54: 423-429. 1986
Kerr, DJ; Kaye, SB; Graham, J; Cassidy, J; Harding, M; Setanoians, A; McGrath, JC; Vezin, WR;
Cunningham, D; Forrest, G; Soukop, M. Phase I and pharmacokinetic study of LM985. Cancer Res 46: 3142-3246. 1986
Kerr, DJ; Graham, J; Cummings, J; Morrison, JG; Thompson, GG; Brodie, MJ; Kaye, SB The effect of
verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 18: 239-242. 1986
Kaye, SB; Cummings, J; Kerr, DJ. How much does liver disease affect the pharmacokinetics of adriamycin? Eur J Cancer Clin Oncol 21 8: 893-895. 1985
Kerr, DJ; Graham, J; Blackie, RG; Cunningham, D; Kaye, SB. The relationship between steady-state plasma levels of metoclopramide and control of cis-platinum induced emesis. Br J Pharmacol 20: 426-
427. 1985
Kerr, DJ; Kerr, AM; Freshney, I; Kaye, SB. Comparative intracellular uptake of adriamycin and 4'-deoxydoxorubicin by non-small cell lung tumor cells in culture and its relationship to cell survival.
Biochem Pharmacol 35 16: 2817-2823. 1985
Kaye,S.B; Cummings,J; Kerr,D.J. How much does liver disease affect the pharmacokinetics of
adriamycin? Eur.J.Cancer.Clin.Oncol. 1985 Aug; 21(8): 893-5
Section 3: Gene Therapy
Akita N, Maruta F, Seymour L, Kerr DJ, Parker AL, Asai T, Oku N, Nakayama J and Miyagawa S.
Identification of oligopeptides binding to peritoneal tumours of gastric cancer. Cancer Science. Vol 97 (1) 1075-1081. 2006
Palmer DH, Chen MJ, Searle PF, Kerr DJ, Young LS. Inhibition of NF-kappaB enhances the
cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy. Gene Ther. 2005 Aug;12(15):1187-97.
42
Ming-Jen Chen, Nicola K. Green, Gary M. Reynolds, Joanne R. Flavell, Vivien Mautner, David J. Kerr,
Lawrence S. Young, Peter F. Searle. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene
Therapy. 1-11. 2004
Palmer, D H, Mautner V, Mirza D, Oliff S, Gerristen W, Van Der Sijp J R, Hubscher S, Reynolds G,
Bonney S, Rajaratnam R, Hull D, Horne M, Ellis J, Mountain A, Hill Simon, Harris PA, Searle PF, Young LW, James ND and Kerr DJ. Virus-Directed Enzyme Prodrug Therapy: Intratumoural Administration of
a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
Journal of Clinical Oncology. 22: 1546-1552, 2004.
Chen MJ, Green NK, Reynolds GM, Flavell JR, Mautner V, Kerr DJ, Young LS, Searle PF.Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-
deleted oncolytic adenovirus vector. Gene Ther. 2004 Jul;11(14):1126-36.
Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI, Guise C, Jaberipour M, James ND, Mautner
V, Young LS, Kerr DJ, Mountain A, White SA, Hyde EI. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol. 2004 Nov;31(11):811-6.
Palmer Green NK, Kerr DJ, Mautner V, Harris PA, Searle PF. The nitroreductase/CB1954 enzyme-
prodrug system Methods Mol Med. 2004;90:459-77 Green NK, McNeish IA, Doshi R, Searle PF, Kerr DJ, Young LS. Immune enhancement of nitroreductase-induced cytotoxicity: Studies using a bicistronic adenovirus vector. Int J Cancer. 2003; 104(1): 104-
12.
Palmer DH, Chen MJ, Kerr DJ. Taking Gene Therapy into the Clinic. Journal of Biomedicine and
Biotechnology. 2003; 71-77.
Kerr, DJ, Seymour, LW, & Maruta. Gene Therapy for colorectal cancer. Expert Opinion Biol. (2003)
3 (5): 779-788
Kerr DJ. Clinical development of gene therapy for colorectal cancer. Nature Reviews Cancer, (2003) 3 615-622.
Palmer D H, Milner A E, Kerr D J and Young L S. Mechanism of cell death induced by the novel enzyme-
prod -fluorouracil.
British Journal of Cancer (September 2003), Volume 89, Number 5, Pages 944-950
Knox RJ, Burke PJ, Chen S and Kerr DJ. CB 1954: From the Walker Tumor to NQO2 and VDEPT. Current Pharmaceutical Design, (2003), 9: 2091-2104
Palmer DH, Milner AE, Kerr DJ, Young LS. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
Br J Cancer. 2003 Sep 1;89(5):944-50.
Kerr DJ, Seymour LW, Maruta F. Gene therapy for colorectal cancer. Expert Opin Biol Ther. 2003 Aug;3(5):779-88.
Maruta F, Parker AL, Fisher KD, Murray PG, Kerr DJ, Seymour LW. Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of
human umbilical veins. J Drug Target. 2003 Jan;11(1):53-9.
43
Maruta,F; Parker,A.L; Fisher,K.D; Hallissey,M.T; Ismail,T; Rowlands,D.C; Chandler,L.A; Kerr,D.J;
Seymour,L.W. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer-Gene-Ther. 2002 Jun; 9(6): 543-52
Palmer DH, Mautner V, Kerr DJ. Clinical experience with adenovirus in cancer therapy. Current
Opinion in Molecular Therapeutics. 4(5): 423-434 (2002).
Chen, M.J., Chung-Faye, G.A., Searle, P.F., Young, L.S., and Kerr, D.J. (2001). Gene Therapy for colorectal cancer: therapeutic potential. BioDrugs 15, 357-67.
Chung-Faye, G., Palmer, D., Anderson, D., Baddeley, J., Hussain, S, Murray, P.I., Searle, P., Seymour, L., Harris, P.A., Ferry, D., And Kerr, D.J. (2001). Virus-directed, enzyme prodrug therapy with
nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 7, 2662-8.
Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V, Searle PF*, Kerr DJ. In vivo
gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine
deaminase and uracil phosphoribosyltransferase.. Gene Ther 2001;8(20):1547-54
Djeha AH, Thomson TA, Leung H, Searle PF, Young LS, Kerr DJ. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid
tumors. Mol Ther 2001;3(2):233-40
Chung-Faye GA, Kerr DJ, Young LS, Searle PF. Gene therapy strategies for colon cancer. Mol Med Today, 6: 82-7 (2000)
Djjeha, A.H., Hulme, A., Mountain, A., Young, L.S., Searle, P.F., Kerr, D.J., and Wrighton, C.M. (2000). Expression E.coli B nitroreductase in established human tumor xenografts in mice results in antitumoral
and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Therapy 7, 721 –731.
Weedon,S.J; Green,N.K; McNeish,I.A; Gilligan,M.G; Mautner,V; Wrighton,C.J; Mountain, A; Young,L.S; Kerr,D.J; Searle,P.F. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus
vector-mediated expression of E. coli nitroreductase. Int-J-Cancer. 2000 Jun 15; 86(6): 848-54
Green, N.K., Weedon, S.J., McNeish, I.A., Mautner, V., Young, L.S., Kerr, D.J., and Searle, P.F. (1999). Gene Therapy for cancer: In vivo killing of tumour cells expressing E-coli nitroreductase following
administration of the prodrug CB1954. Gene Therapy 6, 33.
Murray, P.G.,Billingham, L.J., Hassan, H.T., Flavell, J.R., Nelson, P.N., Scott, K., Reynolds, G., Constandinou, C.M., Kerr, D.J., Devey, E.C., Crocker, J., and Young, L.S. (1999). Effect of Epstein-Barr
virus infection on response to chemotherapy and survival in Hodgkin’s disease. Blood 94, 442-447.
Grove JI, Searle PF, Weedon SJ, Green NK, McNeish IA, Kerr DJ. Virus-directed enzyme prodrug therapy
using CB1954. Anti-Cancer Drug Design, 14, 461-472 (1999)
Traunecker, H.C., Stevens, M.C.G., Kerr, D.J., and Ferry, D.R (1999). The acridonecarboxamide
GF120918 potently reverses P-glycoprotein – mediated resistancein human sarcoma MES-Dx5 cells. British Journal of Cancer 81, 942-951.
Searle, P.F., Weedon, S.J., McNeish, I.A., Gilligan, M.G., Ford, M.J., Friedlos, F., Springer, C.J., Young,
L.S., and Kerr, D.J. Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954
44
following retroviral or adenoviral transfer of the E-coli nitroreductase gene. Advances in
Experimental Medicine and Biology 451, 107-113. (1998).
Gilligan MG, Knox P, Weedon S, Barton R, Kerr DJ, Searle P and Young LS. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene Therapy
5, 965-974 (1998)
Green NK, Gillian MG, Kerr DJ, Searle PF, Young LS. Gene therapy for cancer: prospects for the
treatment of lung tumours. Molecular Biology of the Lung, Vol. 2, No 10: 183-201 (1998)
McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, Kerr DJ, and Searle PF. Virus directed enzyme prodrug therapy for ovarian and pancreatric cancer using retrovirally delivered E. Coli
nitroreductase and CB1954. Gene Therapy 1998; 5.1061-9.
McNeish IA, Gilligan MG, Green NK, Roberts SM, Kerr DJ, Friedlos F, Springer CJ, and Searle PF. Virus-
directed enzyme prodrug therapy using retrovirally delivered E. coli nitroreductase and CB1954. British Journal of Cancer 1998; 78.155-6.
Herod, JJO; Eliopoulos, AG; Warwick, J; Niedobitek, G; Young, LS; Kerr, DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184. (1996)
Thompson, AM; Steel, CM; Foster, ME; Kerr, D; Paterson, D; Deane, D; Hawkins, RA; Carter, DC; Evans,
HJ Gene expression in oestrogen-dependant human breast cancer xenograft tumours. Br J Cancer 62: 78-84. 1990
45
General Medicine:
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a
prospective cohort study Lee et al
Lancet Published:May 28, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31173-9
Cancer control in war-torn Iraq Alwan N, Kerr D
The Lancet. Oncology 19(3):291-292 Mar 2018
The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer
Care. Kerr D, Arnold D, Blay J-Y, Buske C, Carrato A, Gerritsen W, Peeters M The oncologist 25(1):e1-e4 Jan 2020
How to Prioritize Cancer Care for Countries in Transition, pp 13-23, 2016 Stewart Kerr, David Kerr in
Cancer Care in Countries and Societies in Transition, Springer International Publishing Ed M Silbermann
Publication and Dissemination of Research Findings, pp 201-212, 2016 Rebecca Johnson , David Kerr
in Cancer Care in Countries and Societies in Transition, Springer International Publishing Ed M Silbermann
Suleman M, Ali R and Kerr DJ. Health Diplomacy: a new approach to the Muslim world? Globalisation and Health 10:50, 2014
Adewole I et al. Building capacity for sustainable research programmes for cancer in Africa. Nature
Reviews Clinical Oncology, published on-line, March, 2014
Kerr DJ and Midgley,R: Can we treat cancer for a dollar a day. New England Journal of Medicine,
363:801-803, 2010
Kerr DJ and Scott M. British Lessons on Health Care Reform. Perspective, New England Journal of Medicine. 2009 Sep 24;361(13):e21.
Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea RW, Shepherd S, Stanley A, Sweeney A, Ilde J Wheatley K, on behalf of the WARP Collaborative Group, Warfarin thromboprophylaxis in
cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet. Feb 2009, 373, 567-574.
Lingwood R, Boyle P, Milburn A, Ngoma T, Arbuthnott J, McCaffrey R, Kerr S and Kerr D. The
challenge of cancer control in Africa. Nature Reviews Cancer. 2008, Vol 8: 298-403
Mager, S R, Oomen MHA, Morente MM, Ratcliffe C, Knox K, Kerr DJ, Pezzella F, Riegman PHJ. Standard
operating procedure for the collection of fresh frozen tissue samples. European Journal of Cancer. 43: 828-834, 2007.
Kerr F and Kerr DJ. Do we bear any moral responsibility to improving cancer care in Africa? Annals of Oncology. 17: 1730-1731, 2006
Khayat D, Kerr DJ. Opinion: Science and Society: A new model for cancer research in France. Nature
Reviews Cancer. 645-651, 2006.
Ref: Cowley AR, Davis J, Dilworth JR, Donnelly PS, Dobson R, Nightingale A, Peach JM, Shore B, Kerr
DJ, Seymour L. Fluorescence studies of the intra-cellular distribution of zinc bis (thiosemicarbazone) complexes in human cancer cells. Chem Commun, 845-847, 2005.
46
Cowley A R., Davis J, Dilworth J, Donnelly P, Dobson R, Nightingale A, Peach J M., Shore B, Kerr D and
Seymour L. Contribution of academic research to discovery and development of medicines: current status and future opportunities. European Journal of Pharmaceutical Sciences. 24: 245-252.
2005. .
Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw KA,
Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS, Kasler M, Kerr DJ, Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, Martin-Moreno JM, McVie JG, Mendelsohn J,
Napalkov NP, Ngoma TA, Park JG, Philip T, Potschke-Langer M, Poudal HN, Rajan B, Ringborg U, Rodger A, Seffrin JR, Shanta V, Shrestha MM, Thomas R, Tursz T, de Valeriola D, Veronesi U, Wiestler OD,
Zaridze D, Zatonski W, Zeng YX. Curbing tobacco's toll starts with the professionals: World No Tobacco Day. Lancet. 2005 Jun 11-17;365(9476):1990-2
Couvreur P, Barguer D, Crommelin DJ, Duchene D, Engels JW, Kerr DJ, Krogsgaard-Larsen P, Meijer DK, Paoletti R, Wagner E; EUFEPS. EUFEPS report. Contribution of academic research to discovery
and development of medicines: current status and future opportunities. Eur J Pharm Sci. 2005 Feb;24(2-3):245-52.
Knox K and Kerr DJ. Establishing a national tissue bank for surgically harvested cancer tissue. British Journal of Surgery. 91: 134-136, 2004.
Kerr DJ and Ratcliffe C. Improving service delivery through an integrated approach to translational
cancer research. Eur Jour of Surgical Oncology. Vol 30, 61-63, 2004.
Kerr D J, Khayat D. The Entente Cordiale – natural and necessary. Annals of Oncology. 15: 1581,
2004
Kerr DJ. NTRAC pioneering a virtual model. The Lancet Oncology. 4:7: 393. 2003
Bevan H, Gowland B, Penny J, Berwick D, Kerr D. Redesigning Cancer Care. 2002. Brit Med Journal.
324:164-166
Spurgeon, P., Barwell, F., and Kerr, D. (2000). Waiting times for cancer patients in England after general practitioners’ referrals: retrospective national survey. British Medical Journal 320, 838-839.
Kerr; D.J. A national cancer plan for the UK. Ann-Oncol. 2000 Dec; 11(12): 1511-2
Stone, P; Richardson,A; Ream,E; Smith,A.G; Kerr,D.J; Kearney,N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann
Oncol. 2000 Aug; 11(8): 971-5
Young A, Kerr DJ. Genetic and immunological therapy for cancer. J R Soc. Med, 93: 10-14 (2000)
Kerr DJ. World summit against cancer for the new millennium the Charter of Paris. Annals of
Oncology, 11: 1-2 (2000)
Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon
A, Morgan M, Fornasiero A, Hoffman W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornbergery U, Trunet PF. On behalf of the Letrozole International Trials Group. Letrozole, a new oral aromatase
inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Onc. 16, 2 :453-461 (1998).
Green S, Miles R, Kerr D. Improving delivery of cancer services – oncology site specialisation. Health
Trends, Vol 30, 3: 80-85 (1998)
47
Mackean MJ, Kerr D, Lesko M, Svedberg A, Hansson F, Jodrell D, Cassidy J. A feasibility study of
roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma. British Journal of Cancer, 78 (12): 1620-1623 (1998)
Kerr, DJ; Griffiths, R and Edwards B Delivering cancer care: a model for the West Midlands. Brit. J.
Cancer, 74: 667-669 (1996)
Hughes, MJ; Kerr, DJ; Cassidy, J; Soukop, M; McGregor, K; Blackburn, N; Yosef, H; Kaye, SB.A pilot
study of combination therapy with interferon-a-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours. Annals of Oncology 7: 208-210 (1996)
Baban, DF; Murray, JA; Earl, HM; Kerr, DJ: Seymour, LW Quantitative analysis of vascular endothelial
growth factor expression in chronic lymphocytic leukaemia. Int J Oncol 8 1: 29-34 (1996)
Herod, JJO; Kerr, DJ, Luesley, DM. Mechanisms of resistance to platinum chemotherapeutic agents.
Contemp Rev Obstet Gynaecol 7: 25-28 (1995)
Miles, R; Kerr, DJ The Calman Report on Cancer Services. Current Obstetrics & Gynaecology 5 4
(1995)
De Takats, PG; Dunn, JA; Kerr, DJ; Morrison, JM Impact of adjuvant chemotherapy in breast cancer on response to tamoxifen at relapse. Cancer Treat Rev 19b: 11-19. (1993)
Franchesci, S; Boyle, P; La Vecchia, C; Burt, AD; Kerr, DJ; MacFarlane, GJThe epidemiology of thyroid
cancer. Critical Reviews in Oncogenesis 41: 25-52 (1993)
Godden, J; Porteous, C; George, WD; Kerr, DJ.Bioassay of Transforming Growth factor-b activity in
acidic protein extracts from primary breast cancer specimens. Anticancer Res 13: 427-432 (1993)
Godden, J; Leake, R; Kerr, DJ. The response of breast cancer cells to steroid and peptide growth
factors. Anticancer Res. 12: 1683-1688. 1992
Kerr, DJ.Factors that make cancers grow. Science and Public Affairs: 31-36. 1992
Russell, J; Khan, MZ; Kerr, DJ; Spandidos, DA. The effect of transfection with the oncogenes H-ras, c-
myc on the radiosensitivity of a mink epithelial cell line. Radiation Research 130: 113-116. 1992
Symonds, RP; Habeshaw, T; Kerr, DJ; Paul, J; Darling, A; Burnett, RA; Sotsiou, F; Linardopoulos, S; Spandidos, DA. No correlation between ras, c-myc and c-jun proto-oncogene expression and prognosis
in advanced carcinoma of cervix. Eur J Cancer 28 10: 1615-1617. 1992
Smart, HE; Canney, P; Kaye, SB; Kerr, DJ. Myelofibrosis associated with seminoma. Clinical Oncology
4: 132. 1992
Knowles, S; Smart, HE; Al-Dawoud, D; Kerr, DJ. Small bowel fistula secondary to endarteritis obliterans complicating chemotherapy for small bowel lymphoma. Brit J Radiology 65: 349-350. 1992
Khan, MZ; Spandidos, DA; Kerr, DJ; McNichol, AM; Lang, JC; de Ridder, L; Freshney, RI. Oncogene transfection of mink lung cells : effect on growth characteristics in vitro and in vivo. Anticancer Res.
11: 1343-1348. 1991
Bissett, D; Kunkeler, L; Zwanenburg, I; Paul, J; Gray, C; Swan, IRC; Kerr, DJ Long-term sequalae of treatment for testicular germ cell tumours. Br J Cancer 62: 655-659. 1990
Leake, R; Kerr, D; Rinaldi, F Steroid hormones and growth factors in breast cancer. Annals NY Acad Sci : 236-241. 1990
48
Cunningham, D; Bradlay, CJ; Forrest, GJ; Hutcheon, AW; Adams, L; Sneddon, M;Harding, M; Kerr, DJ;
Soukop, M; Kaye, SB. A randomised trial of oral nabilone and prochlorperazine compared to intravenous metaclopramide and dexamethasone in the treatment of nausea and vomiting induced by
chemotherapy regimens containing cisplatin or cisplatin analogues.Eur J Cancer Clin Oncol 24 4: 685-689. 1988
Graham, J; Harding, M; Mill, L; Kerr, DJ; Rankin, E; Calman, KC; Kaye, SB Results of treatment of non-seminomatous germ cell tumours : 122 consecutive cases in the West of Scotland 1981-1985. Brit J
Cancer 57 2: 182-185. 1988
James, G; Kerr, DJ; McLelland, A; Davies, DL. General peripheral nerve dysfunction in acromegaly: a study by conventional and novel neurophysiological techniques. Neurology, Neurosurgery and
Psychiatry 50: 886-894. 1987
Kerr, DJ; Halberg, F; Sothern, R; Singh, VH; Alexander, WD. Chronobiologic quantification of thyroid
hormone rhythms. Chimioterapia XII: 526-528. 1987
Kerr, DJ; Singh, VK; Alexander, WD; Beastall, GH. The effect of low dose nocturnal dopamine infusion
on the circadian rhythm of TSH. Clinical Science 72: 737-741. 1987
Tumours of the diffuse endocrine system Kerr, DJ; Anderson, JR; Burt, AD.Europ J Surg Oncol 13: 189-195. 1987
Kerr, DJ; Burt, AD; Holloway, C; Beastall, G The effect of 5-fluorouracil on rat adrenal function. Medical
Oncology and Tumour Pharmaco-Therapy 3 2: 101-104. 1986
Kerr, DJ; Singh, VK; McConnell, N; Tsakiris, D; Junor, B. Thyroid function and dialysate hormone loss
in haemodialysis and chronic ambulatory peritoneal dialysis patients. Nephron 43: 164-169. 1986
Kerr, DJ; Burt, AD; Boyle, P; MacFarlane, GJ; Storer, AM; Brewin, TB. Prognostic factors in thyroid
cancer. Brit J Cancer 54: 475-482. 1986
Kerr, DJ; Singh, VK; Alexander, WD; Sothern, RB; Halberg, I. Chronobiologic quantification of nocturnal low dose dopamine effect on circadian rhythms of thyroid related hormones and prolactin.
Chronobiologia Vol XIII 3: 245-248. 1986
Kerr, DJ; Burt, AB; Brewin, TB; Boyle, P. Divergence between mortality and incidence of thyroid
cancer.Lancet ii: 1932. 1985
Boyle, P; Burt, D; Kerr, DJ.The geographical pathology of thyroid cancer. Technical Report, 2692. Dana Faber Cancer Institute, Harvard University. 1985
Kerr, DJ; McAlpine, I; Dagg, JH. Pseudohyperkalaemia. Lesson of the Week, British Medical Journal, September, p890. 1985
Burt, AB; Kerr, DJ; Boyle, P; Brown, IL. Lymphoid and epithelial markers in small cell anaplastic thyroid
tumours. J.Clin.Pathol. 1985 Aug; 38(8): 893-6
Alexander, WD; Kerr, DJ; Ferguson, MM.First line test of thyroid function.Lancet ii: 647. 1984
Kerr, DJ; Alexander, WD.Is the TRH test usually unnecessary? Lancet ii: 1162. 1984
Kerr, DJ; Elliot, IIL; Hillis, WS Epileptiform seizures and electroencephalographic abnormalities as
manifestations of digoxin toxicity. Brit Med Journal 284: 162. 1982
49
PUBLISHED BOOK CHAPTERS
Midgley RS, Al-Salama H, Merrie A, Mortensen N and Kerr DJ. “Colorectal cancer: a multidisciplinary
approach”. Textbook of Clinical Gastroenterology and Hepatology. In Press. 2009
Midgley RS, Kerr DJ “Systemic adjuvant therapy of colon cancer” in “Colorectal Cancer” Ed. Rougier Ph., Bleiberg H, Wilke HJ. Publ. Martin Dunitz Ltd UK. (1997)
Midgley RS, Kerr DJ (1998) “Adjuvant chemotherapy for colorectal cancer” in “Recent Advances in Surgery” 21.Churchill Livingstone
"Chemoembolism in Cancer Therapy". D J Kerr and S B Kaye in Critical Reviews in Cancer, Ed. S D
Brack, p19-39, 8 1, 1991.
"Drug Metabolism and Cancer". M A Graham, R Riley and D J Kerr. Pharmac. Ther. Vol. 51, p275-
289, 1991. Ed. M J Brodie. Pergamon Press plc.
"The Effect of Angiotensin II on Tumour Blood Flow and the Delivery of Microparticulate Cytotoxic Drugs". D J Kerr, J A Goldberg, J R Anderson, N Willmott, A T Whateley, C S McArdle and J McKillop.
Angiogenesis p339-345. Ed: R Steiner, PB Weisz and R Langer. Birkhauser Verby, 1992.
Graham, MA; Kerr, DJ; Workman, P.Absorption and distribution of anti-cancer drugs. In Florence AT;
Salole, EG eds. Pharmaceutical aspects of cancer chemotherapy. Oxford: Butterworth-Heinemann Ltd, pp 1-26. (1993)
"The clinical evaluation of novel chemotherapeutic agents". Poole, CJ; Kerr, DJ in New Molecular
targets for cancer chemotherapy. Editors Kerr, Workman, P. CRC Press : 195-212, 1994.
"P-glycoprotein, a transporter with allosterically coupled drug-acceptor sites as a target for rational drug
design". Ferry, DR; Kerr, DJ in New molecular targets for chemotherapy. Editors: Kerr, DJ; Workman, P. CRC Press, pp 177-193 (1994)
“Systemic Therapy of colorectal cancer” Midgley RS, Young AM, Ferry D, Kerr DJ, (2000) in “Colorectal Cancer” Ed. McArdle C, Kerr DJ, Boyle P. Publ. ISIS Medical Media Ltd,UK.
“Principles of pharmacokinetics”. Gouyette, A; Kerr, DJ. In Peckham, Pinedo and Veronesi eds Oxford
Textbook of Oncology, Oxford Press, Vol 1, Sect 4.34: 852-864 (1995)
“New and miscellaneous anticancer drugs: future developments in drug design”. Kerr, DJ; Kaye, SB.
In Peckham, Pinedo & Veronesi eds. Oxford Textbook of Oncology 1.Oxford Press, pp 578-585 (1995)
"Principles Pharmacokinetique d'Agents Cytotoxique. A Gouyette and D J Kerr in Oncologie. Ed
T.Tursz, Presse d’Or 1995.
"Gene-transfer therapy and pancreatic cancer". Searle,PF; Green, NK; Young, LS; Kerr, DJ;
Neoptolemos, JP. in Pancreatic Cancer; Molecular and clinical advances chapter 16: 214-223. Editors: Neoptolemos, JP and Lemoine,NR. 1995
"Adjuvant chemotherapy and immunotherapy". DJ Kerr in Colorectal Cancer Chapter 10 pages 151-158. Ed: N S Williams. 1995
Morrison, J and Kerr D. Virus-directed suicide gene therapy. Cancer Therapy Molecular Targets in
Tumor-host Interactions. Editor: George F Weber. Chapter 16: 363-389. 2005
50
Nicum S, Midgley RS, Kerr DJ (2004) Chemotherapy and Radiotherapy for Colorectal Cancer. Recent Advances in Coloproctology-Volume 2
Midgley RS, Merrie A, Mortensen N, Kerr DJ (2004) Multi-disciplinary Care of Colorectal Cancer. In
Gastroenterology and Hepatology: The Modern Clinicians Guide. Ed Weinstein W, Hawkey CJ and
Bosch J. Elsevier Science
Midgley RS (2002) “Systemic adjuvant therapy of colon cancer” in “Colorectal Cancer” Revised edition. Ed. Rougier Ph., Kemeny N, Bleiberg H, Wilke HJ. Publ. Martin Dunitz Ltd UK
Midgley RS, Young AM, Ferry D, Kerr DJ, (2000) “Systemic Therapy of colorectal cancer” in “Colorectal
Cancer” Ed. McArdle C, Kerr DJ, Boyle P. Publ. ISIS Medical Media Ltd,UK.
Midgley RS, Kerr DJ (2000) Is adjuvant chemotherapy for colorectal cancer worthwhile? In: Challenges
in colorectal cancer. Ed Scholefield J. Publ. Blackwell Science,UK. Chapter 11:149-165
Midgley RS, Kerr DJ (1998) “Adjuvant chemotherapy for colorectal cancer” in “Recent Advances in
Surgery” 21.Churchill Livingstone
Midgley RS, Kerr DJ (1997) “Systemic adjuvant therapy of colon cancer” in “Colorectal Cancer” Ed. Rougier Ph., Bleiberg H, Wilke HJ. Publ. Martin Dunitz Ltd UK.
"Advances in Cancer Research" D J Kerr. Chapter 16, p314-325 in Surgical Oncology. Ed. C S
McArdle. Publishers, Butterworth's Ltd.
"Adjuvant treatment of bowel cancer". DJ Kerr and RS Midgley, In: "Surgical Treatment of
Colorectal Cancer". Editor Mansell
Textbook of Clinical GI/Hepato. “Colorectal cancer: a multidisciplinary approach chapter”. Midgley
RS, Al-Salama HM, Merrie A, Mortensen N and Kerr D J. In press
S Kerr and DKerr. How to Prioritize Cancer Care for Countries in Transition. Chapter 2,pp 13-21, in
Cancer Care in Countries in transition, Ed Silberman, Springer, ISBN 978-3-319-22911-9 ISBN 978-3-
319-22912-6 (eBook) DOI 10.1007/978-3-319-22912-6, 2015
R Johnson and D Kerr. Publication and Dissemination of Research. Chapter 10, pp 201-12 in Cancer Research and Clinical trials in Developing Countries, Ed Stefan, Springer, ISBN 978-3-319-18442-5
ISBN 978-3-319-18443-2 (eBook), DOI 10.1007/978-3-319-18443-2, 2015
51
EDITED BOOKS
"New Molecular Targets for Cancer Chemotherapy". Editors DJ Kerr, P Workman, CRC Press 1994.
"Regional Chemotherapy : Principles and Practice". Editors DJ Kerr, CS McArdle. Harwood Academic Publishers 1998.
"Clinical Textbook of colorectal Cancer". Editors DJ Kerr, CS McARdle and P. Boyle. ISIS Academic
Publishers 2000.
"ABC of Colorectal Cancer", British Medical Journal Book Series, Editors DJ Kerr, AM Young and R Hobbs,
2001.
ABC of Colorectal Cancer by Annie Young, Richard Hobbs and David Kerr (Nov 14, 2011)
“Anticancer Therapeutic Development: from laboratory bench to bedside” – Editors B Baguley and D J
Kerr, 2001
“Advances in Colorectal Cancer” Eds Kerr DJ, Bodmer WF, McArdle CS and Pignatelli M. British Medical Bulletin, 64, 2002, Oxford University Press
“Cancer biotherapy an introductory guide”. Eds, Young, Rowett, Kerr. Oxford University Press. 2006.
“Gastrointestinal Oncology: Evidence and Analysis”. Eds, McCulloch, Karpeh, Kerr, Ajani. Informa Healthcare. 2007
‘Clinical Trials Explained: A Guide to Clinical Trials in the NHS for Healthcare Professionals by DJ Kerr,
2005
“Textbook of Gastrointestinal Cancer”. Eds, Jankowski, Kerr, Fong, Blackwells Publishing. 2008
“Oncology Drugs Handbook”, Oxford University Press, Eds Midgley, Middleton, Dickman and Kerr, 2013
‘ How to get better value cancer care’, OffOx press, Gray and Kerr, 2013
“Oxford Textbook of Oncology”, Oxford University Press, DJ Kerr, C Van De Velde, D Haller, M Baumann. 2016
“Oxford Textbook of Cancer Biology”, Oxford University Press, DJ Kerr, Pezzella F . 2019
“Oxford Textbook of Oncology”, Oxford University Press, DJ Kerr, C Van De Velde, Shi Yuankai, D Haller, M Baumann. 2020
JOURNAL EDITORIAL BOARDS
Annals of Oncology – Editor in Chief (1998 – 2006)
Nature Clinical Oncology Reviews
Japanese Journal of Clinical Oncology
Seminars in Oncology
Molecular Oncology
Chinese Clinical Oncology
Journal of Global Oncology – Editor in Chief (2015- present)